Edited (no change to conclusions)

Summary of findings {#CD009855-sec1-0001}
===================

Summary of findings for the main comparisonGovernment training of private for‐profit healthcare providers**Training compared to no training for improving quality of carePopulation:** Private for‐profit providers of healthcare services **Settings:** Kenya and Indonesia (1 study) and Kenya (1 study) **Intervention:** Training **Comparison:** No training**OutcomesImpactsNo of Participants (studies)Certainty of the evidence (GRADE)Quality of care**Both studies show that training probably improves the quality of healthcare services486 pharmacies (2 studies)⊕⊕⊕⊝ Moderate\*\* We downgraded the certainty of evidence by 1 point, because of a moderate risk of selection bias in included studies.\
**GRADE Working Group grades of evidence** **High certainty:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** We are very uncertain about the estimate.

[Table 2](#CD009855-tbl-0002){ref-type="table"}Summary of findings 2Government regulation of private for‐profit healthcare providers**Regulation compared to no regulation for improving quality of carePopulation:** Private for‐profit providers of healthcare services **Settings:** Lao People\'s Democratic Republic **Intervention:** Regulation **Comparison:** No regulation**OutcomesImpactsNo of Participants (studies)Certainty of the evidence (GRADE)Quality of care**Regulation may improve quality of care. The study observed an increase of 34% in the availability of essential materials for dispensing and an increase of 19% in mean orderliness (including the presence of advertisements, and storage of drugs in their original packaging away from sunlight) in the intervention pharmacies compared to the control pharmacies115 pharmacies (1 study)⊕⊕⊝⊝ Low\*\* We downgraded the certainty of the evidence by 2 points, because of a high risk of attrition bias and wide confidence intervals around the effect estimate, ranging from a large benefit to important harm\
GRADE Working Group grades of evidence **High certainty:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** We are very uncertain about the estimate

[Table 3](#CD009855-tbl-0003){ref-type="table"}Summary of findings 3Government training and regulation of private for‐profit healthcare providers**Training and regulation compared to no intervention for improving quality of carePopulation:** Private for‐profit providers of healthcare services **Settings:** Thailand and Vietnam **Intervention:** Training, regulation, and peer influence **Comparison:** No intervention**OutcomesImpactNo of Participants (studies)Certainty of the evidence (GRADE)Quality of care**Training and regulation may improve quality of care379 pharmacies (3 studies)⊕⊕⊝⊝ Low\*\* We downgraded the certainty of evidence by 2 points because of a high risk of attrition bias and heterogeneity of intervention effects. Two studies found that training, regulation, and peer influence may improve quality of care while the third study found little or no effects in the quality of care with the intervention\
GRADE Working Group grades of evidence **High certainty:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** We are very uncertain about the estimate.

Background {#CD009855-sec1-0002}
==========

The public health sector in low‐ and middle‐income countries is not always sufficiently well‐equipped and financed to provide high quality health care that is accessible to all citizens ([@CD009855-bbs2-0052]; [@CD009855-bbs2-0067]). The consequence of this public sector failure has been a proliferation in private providers of healthcare services in most of the countries ([@CD009855-bbs2-0058]; [@CD009855-bbs2-0068]; [@CD009855-bbs2-0073]). Governments have a responsibility to ensure the quality of healthcare services delivered by private providers, to expand the coverage of existing private providers, and to rationalise this coverage with that of public sector providers ([@CD009855-bbs2-0078]). Such government guidance is referred to as public stewardship. However, there is a paucity of high quality research evidence on the effects of public stewardship on the quality and accessibility of private for‐profit health care in low‐ and middle‐income countries ([@CD009855-bbs2-0070]; [@CD009855-bbs2-0078]); thus the need for this review.

Description of the condition {#CD009855-sec2-0001}
----------------------------

The private health sector is not homogeneous, but consists of not‐for‐profit and for‐profit as well as formal and informal providers of healthcare services ([@CD009855-bbs2-0052]; [@CD009855-bbs2-0074]). Private not‐for‐profit healthcare providers refer to healthcare organisations that use any surplus revenues to achieve their goals, rather than distributing them as dividends. On the other hand, the private for‐profit sector refers to the part of the economy that is run by individuals and companies for profit and is not state‐controlled. The consequence of the expansion in the private health sector in LMICs is that (poor) communities spend outsized amounts of money for private healthcare services; at times when cheaper public sector alternatives are available ([@CD009855-bbs2-0058]; [@CD009855-bbs2-0070]). However, the quality of the services provided by the private for‐profit healthcare sector in LMICs is increasingly being questioned ([@CD009855-bbs2-0053]; [@CD009855-bbs2-0078]).

Description of the intervention {#CD009855-sec2-0002}
-------------------------------

The growing concern regarding the technical failures of health care provided by the private for‐profit sector has led to the development of interventions aimed at addressing these limitations, which simultaneously take advantage of the potential for involving the private for‐profit sector to achieve public health goals. This review assessed the public stewardship of private for‐profit healthcare providers in LMICs. Stewardship can be defined as a function of governments responsible for the welfare of their populations ([@CD009855-bbs2-0077]). It involves policy guidance to the whole health system, co‐ordination between actors and regulation of different functions, levels and actors in the system, an optimal allocation of resources and accountability towards all stakeholders. Although many actors have an influence on stewardship, there is a central role for the government in ensuring equity, efficiency and sustainability of the health system ([@CD009855-bbs2-0076]). Therefore, stewardship entails oversight and guidance of the whole system; ensuring strategic policy frameworks exist and are combined with effective oversight, coalition‐building, regulation, attention to system‐design and accountability. The stewardship function involves the role of the government in health and its relation to other actors whose activities impact on health. Public stewardship encompasses government policies, regulatory mechanisms, and implementation strategies for ensuring guidance and accountability in which healthcare services are delivered; in order to protect the public interest ([@CD009855-bbs2-0079]). While ultimately it is the responsibility of government, this does not mean all stewardship functions have to be carried out by central ministries of health ([@CD009855-bbs2-0080]).

Various strategies have been proposed for improving the functioning of the private for‐profit health sector in order to increase the quality, availability, and affordability of health care for poor people in LMICs ([@CD009855-bbs2-0067]; [@CD009855-bbs2-0068]; [@CD009855-bbs2-0070]; [@CD009855-bbs2-0078]). These strategies include regulation, contracting‐out, social marketing, franchising, use of vouchers, training, pay for performance, accreditation, and co‐ordination. The strategies use various markers of success which are analysed by their association with differences in performance of intermediate goals or outcomes ([@CD009855-bbs2-0075]). We focused on three types of strategic interventions, namely, regulation, training, and co‐ordination of private for‐profit providers. In the context of this review, regulation refers to the setting and enforcing of standards for the private for‐profit sector; training involves educating and supporting private for‐profit service providers; and co‐ordination entails organising and creating alliances between private for‐profit and public sector healthcare providers. We excluded public stewardship interventions which are already covered by other Cochrane reviews; including social marketing and franchising ([@CD009855-bbs2-0065]), contracting ([@CD009855-bbs2-0066]), and pay for performance ([@CD009855-bbs2-0081]).

How the intervention might work {#CD009855-sec2-0003}
-------------------------------

Regulatory interventions take the form of rules, enforcement systems and sanction mechanisms, and can be applied at the levels of the healthcare provider, organisation, or facility. At the provider level, regulation may include requirements for pre‐service training, continuing education, licensing, and certification. At the organisational or facility level, regulation may aim to control the location of facilities, their registration, prices, and minimum complement of staff or facilities. For example, pharmaceutical market regulation aims to limit the availability of harmful drugs and unregistered products, minimise drug misuse, control the sale of specific drugs through prescriptions, and control drug manufacture and importation. Training interventions may involve formal educational sessions (educational meetings and workshops), vendor‐to‐vendor education, distribution of guidelines, printed educational materials, educational outreach i.e. a personal visit by a trained government official to private for‐profit healthcare providers in their own settings, or audit and feedback i.e. a summary of the performance of private for‐profit providers over a specified period of time given in a verbal or written format; alone or in combination ([@CD009855-bbs2-0059]; [@CD009855-bbs2-0064]; [@CD009855-bbs2-0069]; [@CD009855-bbs2-0070]). A wide variety of private for‐profit healthcare sector components could be targeted for training, including physicians, pharmacists, midwives, nurses, and traditional healers. Finally, government co‐ordination of private for‐profit health care ensures harmonised minimum standards for health service delivery across geographic areas and social groups ([@CD009855-bbs2-0078]). For instance, the creation of referral systems between the private for‐profit and public sector and ensuring that health professionals in different health sectors understand their roles in disease management. The ultimate aim of government regulation, training, and co‐ordination of the private for‐profit health sector is to promote equity, better health outcomes, and financial protection ([@CD009855-bbs2-0067]).

Why it is important to do this review {#CD009855-sec2-0004}
-------------------------------------

A systematic review published in 2007 found "evidence that effective public‐private partnerships can increase access, improve equity, and raise quality of health services\" ([@CD009855-bbs2-0070]). However, using the GRADE approach ([@CD009855-bbs2-0051]; [@CD009855-bbs2-0060]), this evidence on the effectiveness of interventions for working with the private for‐profit sector to improve the utilisation and quality of health services for the poor in low‐ and middle‐income countries was found to be of low certainty ([@CD009855-bbs2-0082]). The implication of the low certainty of the evidence is that further research on this topic is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. It is possible that additional primary studies may have been conducted on this topic. Therefore, we reviewed the currently available evidence on public sector efforts to work with private for‐profit health service providers to improve the quality of existing healthcare services as well as expand and rationalise their coverage ([@CD009855-bbs2-0078]).  

Objectives {#CD009855-sec1-0003}
==========

To assess the effects of public sector regulation, training, or co‐ordination of the private for‐profit health sector in low‐ and middle‐income countries.

Methods {#CD009855-sec1-0004}
=======

Criteria for considering studies for this review {#CD009855-sec2-0005}
------------------------------------------------

### Types of studies {#CD009855-sec3-0001}

The studies eligible for inclusion in the review were:

randomised trials, including individually‐randomised and cluster‐randomised trials;

non‐randomised controlled trials i.e. experimental studies in which people are allocated to different interventions using methods that are not random;

interrupted time series studies with at least three measurements before and after introducing the intervention; and

controlled before‐after studies with at least two intervention groups and at least two comparable control groups, with simultaneous data collection ([@CD009855-bbs2-0056]).

### Types of participants {#CD009855-sec3-0002}

Studies taking place in low‐ and middle‐income countries as defined by the World Bank. All types of health services provided by for‐profit providers were eligible for inclusion in this review.

### Types of interventions {#CD009855-sec3-0003}

Regulation, training, and co‐ordination of any intensity or duration, implemented by the public sector. The control group received no intervention or an alternative intervention.

### Types of outcome measures {#CD009855-sec3-0004}

The outcomes of interest were as follows.

#### Primary outcomes {#CD009855-sec4-0001}

Quality of care (defined as adherence to recommended practice or guidelines).

#### Secondary outcomes {#CD009855-sec4-0002}

EquityMortality or morbidityAdverse effects (e.g. undesirable impacts on existing public or private services, inappropriate use of services, and distortion in the provision of services)SatisfactionAttitudesCosts of implementing the interventions

Search methods for identification of studies {#CD009855-sec2-0006}
--------------------------------------------

We developed a sensitive and previously validated search strategy for randomised trials, non‐randomised trials, controlled before‐after studies, and interrupted time series studies combined with relevant medical subject headings (MeSH) and free‐text terms relating to health regulation, training and co‐ordination literature for low‐ and middle‐income countries. We placed no language or date restrictions on the search strategy. We translated the MEDLINE (Ovid) search strategy into the other databases using the appropriate controlled vocabulary.

### Electronic searches {#CD009855-sec3-0005}

We searched the following databases for systematic reviews:

Cochrane Database of Systematic Reviews (CDSR) 2015, Issue 4, part of *The Cochrane Library*. [www.cochranelibrary.com](www.cochranelibrary.com) (searched 28 April 2015)Database of Abstracts of Reviews of Effectiveness (DARE) 2015, Issue 1, part of *The Cochrane Library*. [www.cochranelibrary.com](www.cochranelibrary.com) (searched 28 April 2015)Health Technology Assessment Database (HTA) 2015, Issue 1, part of *The Cochrane Library.*[www.cochranelibrary.com](www.cochranelibrary.com) (searched 28 April 2015).

We searched the following databases, with no language or date restrictions, for primary studies:

MEDLINE, Epub Ahead of Print, In‐Process & Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE 1946 to Present, OvidSP (searched 16 June 2016)Science Citation Index and Social Sciences Citation Index 1987 to present, and Emerging Sources Citation Index 2015 to present, ISI Web of Science (searched 3 May 2016 for papers citing included studies)Cochrane Central Register of Controlled Trials (CENTRAL), 2015, Issue 3, part of *the Cochrane Library*. [www.cochranelibrary.com](www.cochranelibrary.com) (including the Cochrane Effective Practice and Organisation of Care (EPOC) Group Specialised Register) (searched 28 April 2015)Embase 1980 to 2015 Week 17, OvidSP (searched 28 April 2015)Global Health 1973 to 2015 Week 16, OvidSP (searched 30 April 2015)WHOLIS, WHO (searched 30 April 2015)Science Citation Index and Social Sciences Citation Index 1975 to present, ISI Web of Science (searched 30 April 2015)Health Management, ProQuest (searched 22 November 2013).

### Searching other resources {#CD009855-sec3-0006}

In April 2016 we searched the following databases and websites for eligible studies:

OpenGrey ([opengrey.eu](opengrey.eu))Grey Literature Report ([greylit.org](greylit.org))World Bank e‐Library ([elibrary.worldbank.org](elibrary.worldbank.org))US National Institutes of Health (NIH) ([nih.gov](nih.gov))United Nations Children\'s Fund (UNICEF) ([unicef.org](unicef.org))Alliance for Health Policy and Systems Research ([who.int/alliance‐hpsr/en](who.int/alliance‐hpsr/en))United States Agency for International Development (USAID) ([usaid.gov](usaid.gov))Gavi, The Vaccine Alliance ([gavi.org](gavi.org))Private Healthcare in Developing Countries ([ps4h.org](ps4h.org))Population Services International (PSI) ([psi.org](psi.org))Shops ([shopsproject.org](shopsproject.org))United Kingdom Department for International Development ([gov.uk/government/organisations/department‐for‐international‐development](gov.uk/government/organisations/department‐for‐international‐development))Center For Health Market Innovations ([healthmarketinnovations.org](healthmarketinnovations.org)World Bank ([worldbank.org](worldbank.org))

**Trial Registries**

International Clinical Trials Registry Platform (ICTRP), Word Health Organization (WHO) ([who.int/ictrp/en](who.int/ictrp/en)) (searched April 2016)ClinicalTrials.gov ([clinicaltrials.gov](clinicaltrials.gov)) (searched April 2016)

We checked the reference lists of identified reviews ([@CD009855-bbs2-0052]; [@CD009855-bbs2-0053]; [@CD009855-bbs2-0058]; [@CD009855-bbs2-0059]; [@CD009855-bbs2-0068]; [@CD009855-bbs2-0070]; [@CD009855-bbs2-0074]; [@CD009855-bbs2-0078]) as well as reference lists of full‐text articles reviewed for inclusion in this review.

Data collection and analysis {#CD009855-sec2-0007}
----------------------------

### Selection of studies {#CD009855-sec3-0007}

Two authors (Leila Abdullahi and Valantine Ndze, Leila Abdullahi and Charles Wiysonge, or Valantine Ndze and Charles Wiysonge) screened the titles and abstracts of outputs from the searches using a pre‐designed screening guide to identify potentially eligible studies. We retrieved the full text of all publications deemed potentially eligible by at least one of the two authors. The two authors then independently examined each of these for eligibility. Each author compiled a list of studies which he or she believed met the inclusion criteria. Both authors compared the lists and resolved discrepancies by discussion and consensus.

### Data extraction and management {#CD009855-sec3-0008}

The two authors independently extracted descriptive and outcome data from each included study using a pre‐designed data collection form. Both authors compared extracted data, resolving any discrepancies by discussion and consensus, failing which a third author would have arbitrated. One of two authors (Leila Abdullahi and Charles Wiysonge) entered the data into Review Manager (RevMan) 5.3 ([@CD009855-bbs2-0072]) and the other author performed double checks to ensure that there were no errors in the data entered.

### Assessment of risk of bias in included studies {#CD009855-sec3-0009}

We assessed the risk of bias based on six standard domains:

Sequence generationConcealment of allocationBlinded or objective assessment of primary outcome(s)Incomplete outcome dataSelective outcome reporting; andOther sources of bias ([@CD009855-bbs2-0063]).

We also used three additional criteria specified by the Cochrane Effective Practice and Organisation of Care Group (EPOC) ([@CD009855-bbs2-0057]):

Similar baseline characteristicsSimilar baseline outcome measuresReliable primary outcome measures; andAdequate protection against contamination.

For each included study, two authors independently reported their assessment of the risk of bias for each domain (i.e. low, high, or unclear) together with a descriptive summary of the information that influenced their judgment. The two authors compared the results of their independent assessments of the risk of bias and resolved any discrepancies by discussion and consensus. Had the two authors failed to reach an agreement, a third author would have arbitrated.

### Measures of treatment effect {#CD009855-sec3-0010}

We grouped measures of treatment effect based on outcome variables and study designs. We recorded and used estimates of effect from the primary analysis reported by the investigators.

We anticipated that there would be important baseline differences between intervention and control groups and planned to base our primary analyses for trials and controlled before‐after studies on estimates of effect that were adjusted for baseline differences. For dichotomous outcomes we planned to calculate the adjusted risk difference as the difference in adherence after the intervention minus the difference before the intervention. A positive risk difference would indicate that compliance with the recommended practice improved more in the intervention group than in the control group (e.g. an adjusted risk difference of 0.11 would indicate an absolute improvement in compliance with targeted behaviours of 11%). For continuous outcomes we planned to calculate the adjusted change relative to the control group as the post‐intervention difference in means minus the baseline difference in means divided by the baseline control group mean. As with the adjusted risk difference, a positive change would indicate that compliance improved more in the intervention group than in the control group. This is a relative effect rather than an absolute effect; the effect size reflects the baseline performance as well as the change in performance and it is not bound between ‐100% and +100%.

We planned to analyse interrupted time series studies using either a regression analysis with time trends before and after the intervention, which adjusts for auto‐correlation and any periodic changes; or any other technique that adjusts for auto‐correlation and periodic changes. We would present results for the outcomes as changes along two dimensions: change in level and change in slope. Change in level is the immediate effect of the policy and change in slope is the change in the trend from pre‐ to post‐intervention. It reflects the long‐term effect of the intervention.

For all measures we planned to calculate 95% confidence intervals (CI).

### Unit of analysis issues {#CD009855-sec3-0011}

We planned that if investigators reported cluster‐randomised trial data as if the randomisation was performed on the individuals rather than the clusters, we would request the intra‐cluster correlation coefficient from the study authors; failing which we would obtain external estimates of the intra‐cluster correlation coefficient from similar studies or available resources. Once established, we would use the intra‐cluster correlation coefficient to re‐analyse the trial data to obtain approximate correct analyses; as described in the Cochrane Handbook for Systematic Reviews of Interventions ([@CD009855-bbs2-0055]). We planned to combine the effect estimates and their corrected standard errors from cluster‐randomised trials with those from parallel group designs using the generic inverse variance method ([@CD009855-bbs2-0055]). If insufficient information was available to control for clustering in this way, we would enter data into RevMan using individuals as the unit of analysis. We would then perform sensitivity analyses to assess the potential bias that may have occurred as a result of the inadequately controlled cluster‐randomised trials. We planned that we would also perform sensitivity analyses if the intra‐cluster correlation coefficients were obtained from external sources to assess the potential biasing effects of inadequately controlled cluster‐randomised trials.

Three included studies were cluster‐randomised trials based on matched pairs of clusters ([@CD009855-bbs2-0002]; [@CD009855-bbs2-0004]; [@CD009855-bbs2-0006]). We did not re‐analyse these data as matching cannot be taken into account in re‐analyses in such studies unless the raw data are available. The studies, however, conducted appropriate analyses of the data, and we have provided the results as reported in the studies. We have re‐analysed the data for the fourth cluster‐randomised trial ([@CD009855-bbs2-0001]). We did not conduct a meta‐analysis.

### Dealing with missing data {#CD009855-sec3-0012}

We planned that where necessary, we would contact the corresponding authors of included studies to supply any unreported data. If the corresponding author did not respond within one week of our request, we planned to contact other authors (copying the corresponding author). If a study reported outcomes only for participants completing the trial or only for participants who followed the protocol, we planned to contact the authors and ask them to provide additional information to permit us to conduct meta‐analyses by intention‐to‐treat. We would describe missing data and dropouts for each included study in the risk of bias table, and discuss the extent to which the missing data could alter our results. We planned to conduct sensitivity analyses to assess the effect of missing data on our primary meta‐analyses. If we had at least 10 studies in a meta‐analysis, we would have explored the impact of including trials with high levels of missing data in the overall assessment of intervention effects by using sensitivity analyses.

For the current version of the review, we did not contact the primary study authors for missing data. We identified levels of attrition for included trials and performed analyses for reported outcomes. All participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. We assumed that missing participants did have the outcome of interest, and did not conduct sensitivity analyses imputing values for the outcome status of missing participants.

### Assessment of heterogeneity {#CD009855-sec3-0013}

Given the variation found across studies in relation to the interventions, study design and outcome measures, we have not conducted a meta‐analysis of study results. A statistical assessment of heterogeneity of results was therefore not done.

If we found homogeneous studies of similar interventions that reported similar outcomes, we would have conducted a meta‐analysis, examined statistical heterogeneity between study results using the Chi^2^ test of homogeneity (with significance defined at the alpha‐level of 10%) ([@CD009855-bbs2-0055]), and quantified any statistical heterogeneity between study results using the I^2^ statistic ([@CD009855-bbs2-0061]).

### Assessment of reporting biases {#CD009855-sec3-0014}

We employed strategies to search for and include relevant unpublished studies in order to reduce possible publication bias. These strategies included searching the grey literature and prospective trial registration databases to overcome time‐lag bias.

### Data synthesis {#CD009855-sec3-0015}

Due to important heterogeneity between studies, a pooled statistical analysis of the results was not possible. Therefore we did a qualitative analysis based on intervention and outcome measures. If we had identified two or more clinically homogenous studies with similar interventions and comparison groups that reported similar outcome measures, we would have used meta‐analysis to estimate the overall effect across those studies. We would have calculated all overall effects, if applicable, using inverse variance methods.

We used the GRADE approach to summarise the certainty of the evidence for each outcome ([@CD009855-bbs2-0060]).The GRADE approach results in an assessment of the certainty of a body of evidence as high, moderate, low, or very low. High certainty evidence implies that \"further research is very unlikely to change our confidence in the estimate of effect\". Moderate certainty evidence means that \"further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate\". Evidence is considered of low certainty if \"further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate\", and very low quality if \"we have very little confidence in the effect estimate\" ([@CD009855-bbs2-0051]).

### Subgroup analysis and investigation of heterogeneity {#CD009855-sec3-0016}

We stratified analysis by type of intervention. We did not find any studies that were similar enough to combine in a meta‐analysis and, therefore, we did not conduct any subgroup analyses.

### Sensitivity analysis {#CD009855-sec3-0017}

If we had found 10 or more studies that were similar enough that it would be sensible to combine them in a meta‐analysis, we would have conducted sensitivity analyses to investigate the robustness of the results to risk of bias (i.e. omitting any studies with high risk of bias) and method of meta‐analysis (i.e. random‐effects versus fixed‐effect).

Results {#CD009855-sec1-0005}
=======

Description of studies {#CD009855-sec2-0008}
----------------------

### Results of the search {#CD009855-sec3-0018}

Our search yielded 20,177 titles and abstracts. After removing 1,419 duplicates , we screened 18,758 records; 18,708 of which were not relevant. We reviewed the 50 potential eligible articles for inclusion. Six of these studies met our inclusion criteria ([@CD009855-bbs2-0001]; [@CD009855-bbs2-0002]; [@CD009855-bbs2-0003]; [@CD009855-bbs2-0004]; [@CD009855-bbs2-0005]; [@CD009855-bbs2-0006]), and we excluded 39 for reasons given in the [Characteristics of excluded studies](#CD009855-sec2-0019){ref-type="sec"}. Five studies were identified after the review was submitted and are awaiting assessment (see [Characteristics of studies awaiting classification](#CD009855-sec2-0020){ref-type="sec"}). We present the search and selection of studies for this review in [Figure 1](#CD009855-fig-0001){ref-type="fig"}.Figure 1Study flow diagram

### Included studies {#CD009855-sec3-0019}

We included six randomised trials on regulation and training of private for‐profit healthcare providers in low‐ and middle‐income countries ([@CD009855-bbs2-0001]; [@CD009855-bbs2-0002]; [@CD009855-bbs2-0003]; [@CD009855-bbs2-0004]; [@CD009855-bbs2-0005]; [@CD009855-bbs2-0006]). One study ([@CD009855-bbs2-0005]) had two components; one being a randomised trial, and the other a non‐randomised trial. Five studies assessed training ([@CD009855-bbs2-0001]; [@CD009855-bbs2-0002]; [@CD009855-bbs2-0003]; [@CD009855-bbs2-0004]; [@CD009855-bbs2-0005]), four studies assessed regulation ([@CD009855-bbs2-0002]; [@CD009855-bbs2-0003]; [@CD009855-bbs2-0004]; [@CD009855-bbs2-0006]), and no study assessed co‐ordination.

#### Description of interventions {#CD009855-sec4-0003}

Two studies ([@CD009855-bbs2-0001]; [@CD009855-bbs2-0005]) assessed only training interventions  (N = 486 pharmacies), one study ([@CD009855-bbs2-0006]) assessed regulation only (N = 115 pharmacies), and three studies ([@CD009855-bbs2-0002]; [@CD009855-bbs2-0003]; [@CD009855-bbs2-0004]) had a multifaceted intervention which combined training, regulation, and peer influence (N = 379 pharmacies). All six studies targeted private pharmacy workers or drug retailers.

##### Training {#CD009855-sec5-0001}

The intervention in the two \'training‐only\' studies consisted of short‐duration training sessions of one or two days in Kenya ([@CD009855-bbs2-0001]; [@CD009855-bbs2-0005]) and Indonesia ([@CD009855-bbs2-0005]). In both studies drug sellers were trained on prescription and dispensing of drugs, and surrogate patients (i.e. simulated clients) were used to assess the effects of the intervention on the quality of care provided by the trained retailers. The training was provided by the Ministry of Health in each country.

##### Regulation {#CD009855-sec5-0002}

One study ([@CD009855-bbs2-0006]) assessed regulation only (N = 115 pharmacies). The regulatory intervention involved three‐month intensive supervision of pharmacy services in the Lao People\'s Democratic Republic, applying sanctions when rules were violated and providing up‐to‐date regulatory documents and information about particular areas needing improvements ([@CD009855-bbs2-0006]). The study compared districts with active regulation to districts with only \"regular supervision\". The \'regular supervision\' intervention package was implemented in the way and speed that would have taken place in the absence of the study. The aim was to let the control districts follow their natural course. The intervention was provided by the Ministry of Health with assistance from the United Nations Children\'s Fund ([@CD009855-bbs2-0006]).

##### Multifaceted intervention {#CD009855-sec5-0003}

Three studies ([@CD009855-bbs2-0002]; [@CD009855-bbs2-0003]; [@CD009855-bbs2-0004]) had a multifaceted intervention which combined training, regulation, and peer influence (N = 379 pharmacies). Each intervention lasted three months, with a gap of four months before the next intervention. The quality of practice after the intervention was assessed through simulated clients. Two studies ([@CD009855-bbs2-0002]; [@CD009855-bbs2-0004]) were performed in Hanoi (Vietnam) with the intervention delivered by the Hanoi Health Bureau and the Hanoi Pharmacy Association. One study ([@CD009855-bbs2-0003]) was performed in both Hanoi (Vietnam) and Bangkok (Thailand); with the intervention delivered by the Hanoi Health Bureau and the Hanoi Pharmacy Association in Vietnam and the Bangkok Health System Research Institute and the Community Pharmacy Association in Thailand. The studies compared pharmacies with the multifaceted intervention to pharmacies without any intervention. All pharmacists who received the multifaceted intervention received all three interventions as a set. Enforcement regulation was performed by pharmacy inspectors while the educational intervention consisted of educational visits by senior researchers. Peer influence involved a number of group leaders and representatives of the pharmacy associations, who attended seminars where the research group informed them about the peer influence strategy and reviewed management.

##### Co‐ordination {#CD009855-sec5-0004}

We did not identify any study that assessed the effects of government co‐ordination of private for‐profit healthcare providers, such as the creation of referral systems between the private for‐profit and public sectors.

#### Description of outcomes {#CD009855-sec4-0004}

All six included studies reported on change in quality of care. The latter was measured using different dimensions in the different studies. One study ([@CD009855-bbs2-0006]) that assessed only regulation measured quality of care through change in the quality of private pharmacy practices (using \"pharmacy indicators\"). The two studies ([@CD009855-bbs2-0001]; [@CD009855-bbs2-0005]) that assessed only training measured quality of care through correct management of childhood malaria or diarrhoea respectively. The three studies with multifaceted interventions ([@CD009855-bbs2-0002]; [@CD009855-bbs2-0003]; [@CD009855-bbs2-0004]) measured quality of care through change in the correct management of tracer conditions, antibiotic dispensing practices, and correct symptomatic treatment of sexually transmitted infections respectively. Two studies ([@CD009855-bbs2-0004]; [@CD009855-bbs2-0002]) reported the cost of implementing the interventions.

No studies reported data on equity, mortality, morbidity, adverse effects, satisfaction, or attitudes.

### Excluded studies {#CD009855-sec3-0020}

We excluded 34 studies ([@CD009855-bbs2-0008]; [@CD009855-bbs2-0007]; [@CD009855-bbs2-0009]; [@CD009855-bbs2-0010]; [@CD009855-bbs2-0011]; [@CD009855-bbs2-0012]; [@CD009855-bbs2-0014]; [@CD009855-bbs2-0015]; [@CD009855-bbs2-0016]; [@CD009855-bbs2-0017]; [@CD009855-bbs2-0018]; [@CD009855-bbs2-0019]; [@CD009855-bbs2-0020]; [@CD009855-bbs2-0021]; [@CD009855-bbs2-0022]; [@CD009855-bbs2-0023]; [@CD009855-bbs2-0024]; [@CD009855-bbs2-0026]; [@CD009855-bbs2-0027]; [@CD009855-bbs2-0028]; [@CD009855-bbs2-0029]; [@CD009855-bbs2-0030]; [@CD009855-bbs2-0031]; [@CD009855-bbs2-0033]; [@CD009855-bbs2-0034]; [@CD009855-bbs2-0035]; [@CD009855-bbs2-0036]; [@CD009855-bbs2-0037]; [@CD009855-bbs2-0038]; [@CD009855-bbs2-0040]; [@CD009855-bbs2-0041]; [@CD009855-bbs2-0042]; [@CD009855-bbs2-0043]; [@CD009855-bbs2-0045]) for reasons given in the table of [Characteristics of excluded studies](#CD009855-sec2-0019){ref-type="sec"}. The most common reason for exclusion was an ineligible study design.

Risk of bias in included studies {#CD009855-sec2-0009}
--------------------------------

We have summarised our judgements about the risk of bias in each included study in [Figure 2](#CD009855-fig-0002){ref-type="fig"} and [Figure 3](#CD009855-fig-0003){ref-type="fig"}.Figure 2Risk of bias graph: review authors\' judgements about each risk of bias item presented as percentages across all included studies.Figure 3Risk of bias summary: review authors\' judgements about each risk of bias item for each included study.

### Allocation {#CD009855-sec3-0021}

The methods for generation of the randomisation sequence and allocation concealment were unclear in all six studies ([@CD009855-bbs2-0001]; [@CD009855-bbs2-0002]; [@CD009855-bbs2-0003]; [@CD009855-bbs2-0004]; [@CD009855-bbs2-0005]; [@CD009855-bbs2-0006]).

### Blinding {#CD009855-sec3-0022}

Outcome assessors were blinded in two studies ([@CD009855-bbs2-0001]; [@CD009855-bbs2-0005]), but there was no description of blinding in the rest ([@CD009855-bbs2-0002]; [@CD009855-bbs2-0003]; [@CD009855-bbs2-0004]; [@CD009855-bbs2-0006]).

### Incomplete outcome data {#CD009855-sec3-0023}

Loss to follow up was moderate to high in the six studies.

### Selective reporting {#CD009855-sec3-0024}

Selective reporting was categorised as unclear since we had no access to the study protocols.

### Other potential sources of bias {#CD009855-sec3-0025}

All studies reported similar baseline characteristics among the intervention and control groups. Two studies ([@CD009855-bbs2-0002]; [@CD009855-bbs2-0003]) reported small differences in the outcome measures at baseline while no description was provided on baseline outcome measures in the rest of the studies. In one cluster‐randomised controlled trial there was some degree of contamination in a cluster that was meant to be a control cluster ([@CD009855-bbs2-0001]), but none of the other studies reported contamination of control clusters with the interventions assessed. We did not have any evidence that other biases were introduced into the remaining studies, over and above the ones reported above.

Effects of interventions {#CD009855-sec2-0010}
------------------------

See: [Table 1](#CD009855-tbl-0001){ref-type="table"}; [Table 2](#CD009855-tbl-0002){ref-type="table"}; [Table 3](#CD009855-tbl-0003){ref-type="table"}

### Primary outcome {#CD009855-sec3-0026}

All six included studies reported effects on quality of care; although quality of care was measured using different indicators. Three studies focused on improving treatment of childhood illnesses such as acute respiratory infection, malaria, or diarrhoea ([@CD009855-bbs2-0001]; [@CD009855-bbs2-0002]; [@CD009855-bbs2-0005]); one assessed the quality of treatment of sexually transmitted infections ([@CD009855-bbs2-0004]); and two assessed antibiotic dispensing practices ([@CD009855-bbs2-0003]; [@CD009855-bbs2-0004]).

#### Training {#CD009855-sec4-0005}

Each of the two studies that assessed training alone ([@CD009855-bbs2-0001]; [@CD009855-bbs2-0005]) observed improvements in quality of care. The study conducted in Kenya and Indonesia ([@CD009855-bbs2-0005]) showed an overall improvement in the management of diarrhoea among counter attendants in the intervention pharmacies compared to the controls. The sale of oral rehydration solution in the intervention pharmacies increased by 204% in Kenya (1 trial, 106 pharmacies; RR 3.04, 95%CI 1.37 to 6.75: [Analysis 1.1](#CD009855-fig-00101){ref-type="fig"}) and 41% in Indonesia (1 trial, 87 pharmacies; RR 1.41, 95%CI 1.03 to 1.93: [Analysis 1.1](#CD009855-fig-00101){ref-type="fig"}); compared to control pharmacies. In Kenya ([@CD009855-bbs2-0001]), correct prescription and dispensing of anti‐malarial drugs improved substantially (1 trial, 293 pharmacies; RR 8.76, 95% CI 0.94 to 81.81: [Analysis 1.2](#CD009855-fig-00102){ref-type="fig"}). Using the GRADE approach ([@CD009855-bbs2-0051]) we judged the certainty of evidence on the effects of training on quality of care as moderate ([Table 1](#CD009855-tbl-0001){ref-type="table"}). Although the findings were consistent across the studies, we downgraded the evidence because of a moderate risk of bias in the included studies ([Figure 3](#CD009855-fig-0003){ref-type="fig"}).

#### Regulation {#CD009855-sec4-0006}

In the \'regulation only\' study, conducted in the Lao People\'s Democratic Republic, the distribution and selling of registered pharmaceutical products was regulated in order to protect consumers against unfair practices ([@CD009855-bbs2-0006]). The study observed an increase of 34% in the availability of essential materials for dispensing and an increase of 19% in mean orderliness (including the presence of advertisements, and storage of drugs in their original packaging away from sunlight) in the intervention pharmacies compared to the control pharmacies. \"Information given to customers increased from 35% to 51% and the mixing of different drugs in the same package went down from 17% to 9%. The pharmacies in the active intervention districts showed greater improvements for four of the six pharmacy indicators\" ([@CD009855-bbs2-0006]) . Using the GRADE approach ([@CD009855-bbs2-0051]), we judged the certainty of the evidence on the effects of the regulatory interventions on quality of care as low ([Table 2](#CD009855-tbl-0002){ref-type="table"}). Our main concern with the evidence was the imprecision of the effect estimate.

#### Multifaceted intervention {#CD009855-sec4-0007}

In the multi‐faceted intervention studies ([@CD009855-bbs2-0002]; [@CD009855-bbs2-0003]; [@CD009855-bbs2-0004]), the interventions (regulation, training, and peer influence) were applied in a sequence, and the study design does not permit separation of the effects of the different interventions. The three studies provided inconsistent results regarding the effect of the multiple interventions on quality of pharmacy practice; including the ability to ask questions, give advice, and provide appropriate treatment for four tracer conditions (acute respiratory conditions, malaria, diarrhoea, and sexually transmitted infections). In one study conducted in Vietnam ([@CD009855-bbs2-0002]), knowledge and reported practice among drug sellers improved for three of the four tracer conditions in intervention pharmacies compared to control pharmacies. The second study conducted in Vietnam, ([@CD009855-bbs2-0004]), found that the intervention pharmacies improved substantially in all tracer conditions compared to the control pharmacies. [@CD009855-bbs2-0003] was conducted in both Vietnam and Thailand and had mixed results. Improvements were observed in Vietnam in the dispensers' behaviour for all tracer conditions, but in Thailand improvements occurred in only one of the tracer conditions. We judged the certainty of the evidence on the effects of the multifaceted intervention as low ([Table 3](#CD009855-tbl-0003){ref-type="table"}), because of concerns regarding inconsistency of findings and high risk of bias in the included studies.

### Secondary outcomes {#CD009855-sec3-0027}

Two multifaceted intervention studies reported the cost of the interventions ([@CD009855-bbs2-0002]; [@CD009855-bbs2-0004]). [@CD009855-bbs2-0002] reported the cost incurred for the three interventions in 30 pharmacies to be USD 5700. The [@CD009855-bbs2-0004] study reported that the costs of treating four tracer conditions increased for both intervention and control pharmacies.

No study reported data on equity, mortality, morbidity, adverse effects, satisfaction, or attitudes.

Discussion {#CD009855-sec1-0006}
==========

Summary of main results {#CD009855-sec2-0011}
-----------------------

Our comprehensive search of the literature identified 20,177 records, from which six randomised controlled trials fulfilled our inclusion criteria. In two studies in Kenya and Indonesia, the Ministry of Health offered private drug sellers short training sessions on prescribing and dispensing drugs. These sellers were compared to drug sellers who were not offered training. The studies suggest that training probably improves the quality of healthcare services. In one study in the Lao People's Democratic Republic, the Ministry of Health supervised private pharmacy services in certain districts over a three‐month period, applied sanctions when rules were broken, and offered information about areas needing improvement. These districts were compared to districts without this enhanced supervision. The study suggests that this enhanced regulation may improve quality of care. In three studies in Vietnam and Thailand, private pharmacies in some districts received educational visits as well as visits from pharmacy inspectors to enforce regulations. These districts were compared to districts that did not receive any visits. The studies suggest that these types of visits may provide mixed results. The review did not find any eligible study that assessed the effects of co‐ordination on quality of care.

Overall completeness and applicability of evidence {#CD009855-sec2-0012}
--------------------------------------------------

Despite the large number of records obtained in our literature search, only six studies with moderate to high risk of bias met our inclusion criteria. All studies were conducted in Africa and Asia; and the results may be applicable to low‐ and middle‐income countries in other continents.

Health worker availability in the public sector is a key barrier to strengthening health systems in LMICs. Effective government interventions to expand the coverage of private for‐profit healthcare providers and rationalise access to their services with that of public sector providers could strengthen health systems in LMICs. However, countries considering the implementation of public stewardship interventions need to assess the human and financial resource capacity of the public sector to properly supervise private providers.

All the studies covered only services of private for‐profit pharmacists. The findings may not be directly transferable to other cadres of private healthcare providers. Therefore, there is a need for studies on other private sector components such as private hospitals, physicians, midwives, nurses, and traditional healers.

There were no studies that reported data on equity, mortality, morbidity, adverse effects, satisfaction, or attitudes. If training or regulatory interventions are directed at providers that serve disadvantaged populations they could help to decrease inequity. However, intervention effects could vary across settings, for example between rural and urban areas, because of the distribution of private providers in these different areas. Expanding the coverage of private for‐profit providers could reduce inequity if, for example, access to the private sector is available where access to the public sector is limited. However, if private for‐profit providers are unavailable in underserved areas, expanding access to private providers may increase inequity between urban and rural areas.

There was no rigorous evaluation of the cost implications of implementing the interventions, thus this review does not provide evidence on investment in private for‐profit providers on quality of care in low‐ and middle‐ income countries. The structure and specific tasks associated with a particular public stewardship function will determine the costs. Given these uncertainties, implementation of public sector regulation, training or co‐ordination of private for‐profit healthcare providers should be accompanied by a robust framework for monitoring the costs and impacts of the interventions.

Much of the currently available literature on training and regulation of private for‐profit providers in low‐ and middle‐income countries is descriptive rather than evaluative, detailing experiences that may have great potential without rigorously testing their effectiveness ([@CD009855-bbs2-0053]; [@CD009855-bbs2-0070]; [@CD009855-bbs2-0078]; [@CD009855-bbs2-0082]). Well‐designed studies evaluating public stewardship functions are therefore needed before these are implemented on a large scale in low‐income countries.

### Certainty of the evidence {#CD009855-sec3-0028}

Using the GRADE approach, we judged the certainty of evidence on the effects of training interventions on quality of care as moderate; which implies that "further research is likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate". We rated the certainty of evidence on regulation and the multifaceted intervention as low, which means that "further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate" ([@CD009855-bbs2-0051]). Our main concerns with the evidence were limitations of the included studies, wide confidence intervals around the effect estimates, and heterogeneity of intervention effects.

Potential biases in the review process {#CD009855-sec2-0013}
--------------------------------------

We minimised potential biases in the review process by adhering to Cochrane guidelines ([@CD009855-bbs2-0062]). We conducted comprehensive searches without limiting the searches to a specific language. Two authors independently assessed study eligibility, extracted data, and assessed the risk of bias in each included study.

Agreements and disagreements with other studies or reviews {#CD009855-sec2-0014}
----------------------------------------------------------

Despite the widespread availability of private healthcare services in low‐ and middle‐income countries, there is a shortage of systematic reviews that have assessed interventions showing how governments have worked with the private for‐profit providers to achieve public health goals ([@CD009855-bbs2-0054]; [@CD009855-bbs2-0068]; [@CD009855-bbs2-0070]; [@CD009855-bbs2-0071]; [@CD009855-bbs2-0078]). To the best of our knowledge, our review is the most comprehensive and up‐to‐date assessment of the evidence on the effects of training, regulation, and co‐ordination of private‐for‐profit health care in low‐ and middle‐income countries.

In 2003 Hugh Waters and colleagues published a review that assessed the evidence available concerning public sector efforts to work with private health service providers and other components of the private sector, in order to both improve the quality of their services and to rationalise and expand their coverage ([@CD009855-bbs2-0078]). The review focused on interventions aimed at regulating, contracting, financing, social marketing, training, co‐ordinating, and informing private providers in low‐ and middle‐income countries. The review authors searched Pubmed and Popline databases, and reference lists of included articles, for both published and unpublished literature from 1980 onwards. They included 42 studies including six 'controlled' trials comparing results in two or more groups; 10 studies with a pre‐post evaluative component, but no comparison group; four cross‐sectional studies; and 22 descriptive case studies. [@CD009855-bbs2-0078] found that although governments are gaining experience in using the tools of contracting, regulating, financial incentives, training, co‐ordinating, and informing to influence the private sector, the evidence on the effectiveness of these interventions remains weak.

In 2007 Edith Patouillard and co‐workers published a related review, which assessed the effectiveness of interventions on working with the private for‐profit sector to improve utilisation of quality health services by the poor in low‐ and middle‐income countries ([@CD009855-bbs2-0070]). Interventions of interest to the review authors included social marketing, use of vouchers, pre‐packaging of drugs, franchising, training, regulation, accreditation, and contracting‐out. They conducted a comprehensive search of peer‐reviewed and grey literature for eligible studies; focusing on studies which evaluated the impact of interventions on utilisation or quality of services, or both, and which provided information on the socioeconomic status of the beneficiary populations. The review authors identified 52 eligible studies; five provided data on the average socioeconomic status of recipient communities and five provided data on the distribution of benefits across socioeconomic groups. [@CD009855-bbs2-0070] concluded that it is not possible to prove from the available literature that private sector interventions benefit the poor and improve equity. However, they argue that the fact that many such interventions have operated successfully in relatively poor settings indicates that the interventions do benefit the poor. The authors went on to recommend that better evidence of the equity impact of interventions working with the private sector is needed for more robust conclusions to be drawn.

There are marked differences between these two previous reviews ([@CD009855-bbs2-0070]; [@CD009855-bbs2-0078]) and the current systematic review. Although the authors of the two previous reviews conducted literature searches that were relatively comprehensive, they do not explicitly say whether they undertook duplicate study selection and data extraction and do not report reliable criteria for assessing the risk of bias in included studies. They do not provide appropriate description of the characteristics of included studies and do not seem to synthesise data from included studies using reliable methods. In addition, much of the data reported in the reviews is descriptive rather than evaluative, detailing experiences that may have great potential without rigorously testing their effectiveness. Most of the studies included in the reviews were not set up as research projects ([@CD009855-bbs2-0070]; [@CD009855-bbs2-0078]). Furthermore, the two reviews included studies in which the stewardship functions were carried out by the public sector as well as those in which the functions were carried out by non‐governmental organisations (NGO). We acknowledge that while ultimately public stewardship is the responsibility of government, this does not mean all stewardship functions have to be carried out by the public sector. While we recognise the importance of private sector interventions implemented by NGOs, their characteristics and incentives are likely to differ from those implemented by government. We included one study in our review ([@CD009855-bbs2-0001]), which was published after publication of the two previous reviews ([@CD009855-bbs2-0070]; [@CD009855-bbs2-0078]).

To the best of our knowledge, our review is the most comprehensive and up‐to‐date assessment of the evidence on the effects of training, regulation, and co‐ordination of private for‐profit healthcare providers in low‐ and middle‐income countries. Some recent Cochrane reviews have assessed public stewardship interventions not covered in our review; such as social marketing and franchising ([@CD009855-bbs2-0065]), contracting ([@CD009855-bbs2-0066]), and pay for performance ([@CD009855-bbs2-0081]). [@CD009855-bbs2-0065] did not find any eligible studies that assessed the effects of social franchising on access to, and the quality of, health services in low‐ and middle‐income countries. We are therefore uncertain about the effects of social franchising as a public stewardship function. [@CD009855-bbs2-0066] examined the effects of contracting out and included three studies, all conducted in low‐ and middle‐income countries. The review found that contracting out services to non‐state not‐for‐profit providers may increase access to and utilisation of health services, improve patient outcomes, and reduce household health expenditures. None of the three included studies presented evidence on whether contracting out was more effective than making a similar investment in the public sector. [@CD009855-bbs2-0081] found nine studies that assessed the effects of pay‐for‐performance schemes on the provision of healthcare and health outcomes in low‐ and middle‐income countries. The review found that it is uncertain whether pay‐for‐performance improves provider performance, the utilisation of services, patient outcomes or resource use in low‐ and middle‐income countries. Unintended effects of pay‐for‐performance schemes might include adverse selection (for example, excluding high‐risk people from care in order to obtain better performance), deception (i.e. inaccurate or false reporting), and distortion (i.e. ignoring important tasks that are not rewarded with incentives).

Authors\' conclusions {#CD009855-sec1-0007}
=====================

This review provides different levels of strength for the currently available evidence on the effectiveness of the three public stewardship interventions. The finding that training probably improves quality of care implies that monitoring of the impact is likely to be needed and an impact evaluation may be warranted if government training of private for‐profit providers is implemented in low‐ and middle‐income countries. The low certainty of the evidence for regulation implies that an impact evaluation is warranted if government regulation of private for‐profit providers is implemented in low‐ and middle‐income countries. We found no studies on the effects of government co‐ordination of private providers.Rigorous evaluations of the interventions assessed in this review (as well as other public stewardship interventions) should assess cost implications, patient outcomes, and impacts on equity; in addition to quality of care. Given that there was no evidence on the impact of the interventions on equity, the challenge for the future is to design evaluations and report results in ways that can assess equity clearly, and indicate how equity can be enhanced.
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**DARE and HTA, Cochrane Library**

IDSearchHits\#1MeSH descriptor: \[Public‐Private Sector Partnerships\] this term only8\#2MeSH descriptor: \[Private Sector\] this term only41\#3MeSH descriptor: \[Private Practice\] this term only84\#4MeSH descriptor: \[Hospitals, Private\] this term only16\#5MeSH descriptor: \[Privatization\] this term only2\#6privat\*4370\#7\#2 or \#3 or \#4 or \#5 or \#64370\#8MeSH descriptor: \[Public Sector\] this term only51\#9MeSH descriptor: \[Public Policy\] this term only53\#10MeSH descriptor: \[Health Policy\] this term only338\#11\[mh \^\"state medicine\"\]460\#12MeSH descriptor: \[State Dentistry\] this term only7\#13MeSH descriptor: \[Health Care Reform\] this term only34\#14MeSH descriptor: \[Health Planning\] this term only64\#15MeSH descriptor: \[Social Control, Formal\] this term only30\#16MeSH descriptor: \[Law Enforcement\] this term only32\#17MeSH descriptor: \[Government\] 2 tree(s) exploded813\#18MeSH descriptor: \[Government Programs\] this term only30\#19MeSH descriptor: \[Government Regulation\] this term only14\#20MeSH descriptor: \[Facility Regulation and Control\] this term only3\#21MeSH descriptor: \[Policy Making\] this term only47\#22MeSH descriptor: \[Jurisprudence\] this term only75\#23MeSH descriptor: \[Mandatory Reporting\] this term only10\#24MeSH descriptor: \[Politics\] this term only40\#25MeSH descriptor: \[Legislation as Topic\] this term only8\#26MeSH descriptor: \[Legislation, Hospital\] this term only0\#27MeSH descriptor: \[Legislation, Medical\] this term only5\#28MeSH descriptor: \[Legislation, Nursing\] this term only0\#29MeSH descriptor: \[Legislation, Pharmacy\] this term only5\#30MeSH descriptor: \[Legislation, Drug\] this term only15\#31\[mh \^\"legislation, dental\"\]0\#32(public\* or stewardship\* or governance or governing or coordinat\* or co next ordinat\* or legislat\* or regulat\* or government\* or law or laws or act or acts or policy or policies or politics or reform\* or control\* or supervis\* or monitor\*)911896\#33\#8 or \#9 or \#10 or \#11 or \#12 or \#13 or \#14 or \#15 or \#16 or \#17 or \#18 or \#19 or \#20 or \#21 or \#22 or \#23 or \#24 or \#25 or \#26 or \#27 or \#28 or \#29 or \#30 or \#31 or \#32912008\#34MeSH descriptor: \[Physician\'s Practice Patterns\] this term only1104\#35MeSH descriptor: \[Nurse\'s Practice Patterns\] this term only62\#36MeSH descriptor: \[Dentist\'s Practice Patterns\] this term only20\#37MeSH descriptor: \[Health Knowledge, Attitudes, Practice\] this term only3833\#38MeSH descriptor: \[Malpractice\] this term only13\#39MeSH descriptor: \[Professional Impairment\] this term only0\#40MeSH descriptor: \[Physician Impairment\] this term only4\#41MeSH descriptor: \[Medical Errors\] this term only119\#42MeSH descriptor: \[Diagnostic Errors\] this term only258\#43MeSH descriptor: \[Professional Competence\] this term only211\#44\[mh \^\"medication errors\"\]228\#45\[mh \^\"clinical competence\"\]1999\#46(competence or practice next pattern\* or malpractice or mal next practice or error\*)27575\#47\#34 or \#35 or \#36 or \#37 or \#38 or \#39 or \#40 or \#41 or \#42 or \#43 or \#44 or \#45 or \#4631029\#48MeSH descriptor: \[Education\] this term only498\#49MeSH descriptor: \[Competency‐Based Education\] this term only67\#50MeSH descriptor: \[Education, Public Health Professional\] this term only3\#51MeSH descriptor: \[Education, Medical\] this term only300\#52MeSH descriptor: \[Education, Medical, Continuing\] this term only638\#53MeSH descriptor: \[Education, Nursing\] this term only117\#54MeSH descriptor: \[Education, Nursing, Continuing\] this term only249\#55MeSH descriptor: \[Education, Dental\] this term only110\#56MeSH descriptor: \[Education, Dental, Continuing\] this term only17\#57MeSH descriptor: \[Education, Pharmacy\] this term only36\#58\[mh \^\"education, pharmacy, continuing\"\]27\#59(educat\* or train or training or trained or colloquium\* or conference\* or course\* or lecture\* or meeting\* or seminar\* or support\* or symposi\* or workshop\*)383851\#60\#48 or \#49 or \#50 or \#51 or \#52 or \#53 or \#54 or \#55 or \#56 or \#57 or \#58 or \#59383851\#61MeSH descriptor: \[Delivery of Health Care\] this term only751\#62MeSH descriptor: \[Quality of Health Care\] this term only933\#63MeSH descriptor: \[Quality Assurance, Health Care\] this term only741\#64MeSH descriptor: \[Quality Improvement\] this term only216\#65MeSH descriptor: \[Total Quality Management\] this term only172\#66MeSH descriptor: \[Outcome and Process Assessment (Health Care)\] this term only2034\#67MeSH descriptor: \[Outcome Assessment (Health Care)\] this term only5357\#68MeSH descriptor: \[Process Assessment (Health Care)\] this term only129\#69MeSH descriptor: \[Guideline Adherence\] this term only748\#70MeSH descriptor: \[Benchmarking\] this term only100\#71MeSH descriptor: \[Standard of Care\] this term only91\#72\[mh \^\"reference standards\"\]357\#73(best next practice or quality or standard\* or benchmark\* or adherence or requirement\*)180929\#74\#61 or \#62 or \#63 or \#64 or \#65 or \#66 or \#67 or \#68 or \#69 or \#70 or \#71 or \#72 or \#73184786\#75(Africa or Asia or Caribbean or \"West Indies\" or \"South America\" or \"Latin America\" or \"Central America\")9614\#76(Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or Argentina or Armenia or Armenian or Aruba or Azerbaijan or Bahrain or Bangladesh or Barbados or Benin or Byelarus or Byelorussian or Belarus or Belorussian or Belorussia or Belize or Bhutan or Bolivia or Bosnia or Herzegovina or Hercegovina or Botswana or Brasil or Brazil or Bulgaria or \"Burkina Faso\" or \"Burkina Fasso\" or \"Upper Volta\" or Burundi or Urundi or Cambodia or \"Khmer Republic\" or Kampuchea or Cameroon or Cameroons or Cameron or Camerons or \"Cape Verde\" or \"Central African Republic\" or Chad or Chile or China or Colombia or Comoros or \"Comoro Islands\" or Comores or Mayotte or Congo or Zaire or \"Costa Rica\" or \"Cote d\'Ivoire\" or \"Ivory Coast\" or Croatia or Cuba or Cyprus or Czechoslovakia or \"Czech Republic\" or Slovakia or \"Slovak Republic\")42820\#77(Djibouti or \"French Somaliland\" or Dominica or \"Dominican Republic\" or \"East Timor\" or \"East Timur\" or \"Timor Leste\" or Ecuador or Egypt or \"United Arab Republic\" or \"El Salvador\" or Eritrea or Estonia or Ethiopia or Fiji or Gabon or \"Gabonese Republic\" or Gambia or Gaza or Georgia or Georgian or Ghana or \"Gold Coast\" or Greece or Grenada or Guatemala or Guinea or Guam or Guiana or Guyana or Haiti or Honduras or Hungary or India or Maldives or Indonesia or Iran or Iraq or \"Isle of Man\" or Jamaica or Jordan or Kazakhstan or Kazakh or Kenya or Kiribati or Korea or Kosovo or Kyrgyzstan or Kirghizia or \"Kyrgyz Republic\" or Kirghiz or Kirgizstan or \"Lao PDR\" or Laos or Latvia or Lebanon or Lesotho or Basutoland or Liberia or Libya or Lithuania)40756\#78(Macedonia or Madagascar or \"Malagasy Republic\" or Malaysia or Malaya or Malay or Sabah or Sarawak or Malawi or Nyasaland or Mali or Malta or \"Marshall Islands\" or Mauritania or Mauritius or \"Agalega Islands\" or Mexico or Micronesia or \"Middle East\" or Moldova or Moldovia or Moldovian or Mongolia or Montenegro or Morocco or Ifni or Mozambique or Myanmar or Myanma or Burma or Namibia or Nepal or \"Netherlands Antilles\" or \"New Caledonia\" or Nicaragua or Niger or Nigeria or \"Northern Mariana Islands\" or Oman or Muscat or Pakistan or Palau or Palestine or Panama or Paraguay or Peru or Philippines or Philipines or Phillipines or Phillippines or Poland or Portugal or \"Puerto Rico\")17933\#79(Romania or Rumania or Roumania or Russia or Russian or Rwanda or Ruanda or \"Saint Kitts\" or \"St Kitts\" or Nevis or \"Saint Lucia\" or \"St Lucia\" or \"Saint Vincent\" or \"St Vincent\" or Grenadines or Samoa or \"Samoan Islands\" or \"Navigator Island\" or \"Navigator Islands\" or \"Sao Tome\" or \"Saudi Arabia\" or Senegal or Serbia or Montenegro or Seychelles or \"Sierra Leone\" or Slovenia or \"Sri Lanka\" or Ceylon or \"Solomon Islands\" or Somalia or Sudan or Suriname or Surinam or Swaziland or Syria or Tajikistan or Tadzhikistan or Tadjikistan or Tadzhik or Tanzania or Thailand or Togo or \"Togolese Republic\" or Tonga or Trinidad or Tobago or Tunisia or Turkey or Turkmenistan or Turkmen or Uganda or Ukraine or Uruguay or USSR or \"Soviet Union\" or \"Union of Soviet Socialist Republics\" or Uzbekistan or Uzbek or Vanuatu or \"New Hebrides\" or Venezuela or Vietnam or \"Viet Nam\" or \"West Bank\" or Yemen or Yugoslavia or Zambia or Zimbabwe or Rhodesia)23854\#80(developing or less\* next developed or \"under developed\" or underdeveloped or \"middle income\" or low\* next income or underserved or \"under served\" or deprived or poor\*) next (countr\* or nation\* or population\* or world)4639\#81(developing or less\* next developed or \"under developed\" or underdeveloped or \"middle income\" or low\* next income) next (economy or economies)31\#82low\* next (gdp or gnp or \"gross domestic\" or \"gross national\")34\#83(low near/3 middle near/3 countr\*)697\#84(lmic or lmics or \"third world\" or \"lami country\" or \"lami countries\")165\#85(\"transitional country\" or \"transitional countries\")11\#86\#75 or \#76 or \#77 or \#78 or \#79 or \#80 or \#81 or \#82 or \#83 or \#84 or \#85121587\#87\#1 and \#863\#88\#7 and \#33 and \#861386\#89\#7 and \#47 and \#86497\#90\#7 and \#60 and \#861000\#91\#7 and \#74 and \#86922\#92\#87 or \#88 or \#89 or \#90 or \#91 in Other Reviews (DARE)15\#93\#87 or \#88 or \#89 or \#90 or \#91 in Technology Assessments (HTA)2

**MEDLINE: Epub Ahead of Print, In‐Process & Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE 1946 to Present, OvidSP**

**\#SearchesResults**1Public‐Private Sector Partnerships/14642Private Sector/80193Private Practice/78114Hospitals, Private/24925Privatization/20026privat\*.ti,ab.710347or/2‐6805628Public Sector/54209Public Policy/2903410Health Policy/5547411State Medicine/5272312State Dentistry/222413Health Care Reform/2987314Health Planning/2094915Social Control, Formal/1129816Law Enforcement/293717exp Government/13233718Government Programs/413919Government Regulation/1905720\"Facility Regulation and Control\"/314421Policy Making/1357222Jurisprudence/2930523Mandatory Reporting/278424Politics/4328925Legislation as Topic/1567626Legislation, Hospital/237927Legislation, Medical/1626928Legislation, Nursing/304729Legislation, Pharmacy/118630Legislation, Drug/921731Legislation, Dental/190232(public\* or stewardship\* or governance or governing or coordinat\* or co ordinat\* or legislat\* or regulat\* or government\* or law or laws or act or acts or policy or policies or politics or reform\* or control\* or supervis\* or monitor\*).ti,ab.551290633or/8‐32576144034Physician\'s Practice Patterns/4721135Nurse\'s Practice Patterns/150336Dentist\'s Practice Patterns/183737Health Knowledge, Attitudes, Practice/8468938Malpractice/2651139Professional Impairment/118140Physician Impairment/216341Medical Errors/1406242Diagnostic Errors/3368343Medication Errors/1129244Professional Competence/2181645Clinical Competence/7382746(competence or practice pattern\* or malpractice or mal practice or error\*).ti,ab.28315747or/34‐4654762548Education/1916949Competency‐Based Education/316450Education, Public Health Professional/68651Education, Medical/5098852Education, Medical, Continuing/2275953Education, Nursing/2975154Education, Nursing, Continuing/2184955Education, Dental/1350256Education, Dental, Continuing/327457Education, Pharmacy/454858Education, Pharmacy, Continuing/80059(educat\* or train or training or trained or colloquium? or conference? or course? or lecture? or meeting? or seminar? or support\* or symposi\* or workshop?).ti,ab.245570460or/48‐59253258361\"Delivery of Health Care\"/7252462\"Quality of Health Care\"/6219663Quality Assurance, Health Care/5204264Quality Improvement/1094365Total Quality Management/1209966\"Outcome and Process Assessment (health care)\"/2324267\"Outcome Assessment (health care)\"/5598268\"Process Assessment (health care)\"/351569Guideline Adherence/2483770Benchmarking/1119571\"Standard of Care\"/136672Reference Standards/3805173(best practice or quality or standard\* or benchmark\* or adherence or requirement\*).ti,ab.184397074or/61‐73205205075Developing Countries.sh,kf.7699876(Africa or Asia or Caribbean or West Indies or South America or Latin America or Central America).hw,kf,ti,ab,cp.21353877(Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or Argentina or Armenia or Armenian or Aruba or Azerbaijan or Bahrain or Bangladesh or Barbados or Benin or Byelarus or Byelorussian or Belarus or Belorussian or Belorussia or Belize or Bhutan or Bolivia or Bosnia or Herzegovina or Hercegovina or Botswana or Brasil or Brazil or Bulgaria or Burkina Faso or Burkina Fasso or Upper Volta or Burundi or Urundi or Cambodia or Khmer Republic or Kampuchea or Cameroon or Cameroons or Cameron or Camerons or Cape Verde or Central African Republic or Chad or Chile or China or Colombia or Comoros or Comoro Islands or Comores or Mayotte or Congo or Zaire or Costa Rica or Cote d\'Ivoire or Ivory Coast or Croatia or Cuba or Cyprus or Czechoslovakia or Czech Republic or Slovakia or Slovak Republic or Djibouti or French Somaliland or Dominica or Dominican Republic or East Timor or East Timur or Timor Leste or Ecuador or Egypt or United Arab Republic or El Salvador or Eritrea or Estonia or Ethiopia or Fiji or Gabon or Gabonese Republic or Gambia or Gaza or Georgia Republic or Georgian Republic or Ghana or Gold Coast or Greece or Grenada or Guatemala or Guinea or Guam or Guiana or Guyana or Haiti or Honduras or Hungary or India or Maldives or Indonesia or Iran or Iraq or Isle of Man or Jamaica or Jordan or Kazakhstan or Kazakh or Kenya or Kiribati or Korea or Kosovo or Kyrgyzstan or Kirghizia or Kyrgyz Republic or Kirghiz or Kirgizstan or Lao PDR or Laos or Latvia or Lebanon or Lesotho or Basutoland or Liberia or Libya or Lithuania or Macedonia or Madagascar or Malagasy Republic or Malaysia or Malaya or Malay or Sabah or Sarawak or Malawi or Nyasaland or Mali or Malta or Marshall Islands or Mauritania or Mauritius or Agalega Islands or Mexico or Micronesia or Middle East or Moldova or Moldovia or Moldovian or Mongolia or Montenegro or Morocco or Ifni or Mozambique or Myanmar or Myanma or Burma or Namibia or Nepal or Netherlands Antilles or New Caledonia or Nicaragua or Niger or Nigeria or Northern Mariana Islands or Oman or Muscat or Pakistan or Palau or Palestine or Panama or Paraguay or Peru or Philippines or Philipines or Phillipines or Phillippines or Poland or Portugal or Puerto Rico or Romania or Rumania or Roumania or Russia or Russian or Rwanda or Ruanda or Saint Kitts or St Kitts or Nevis or Saint Lucia or St Lucia or Saint Vincent or St Vincent or Grenadines or Samoa or Samoan Islands or Navigator Island or Navigator Islands or Sao Tome or Saudi Arabia or Senegal or Serbia or Montenegro or Seychelles or Sierra Leone or Slovenia or Sri Lanka or Ceylon or Solomon Islands or Somalia or Sudan or Suriname or Surinam or Swaziland or Syria or Tajikistan or Tadzhikistan or Tadjikistan or Tadzhik or Tanzania or Thailand or Togo or Togolese Republic or Tonga or Trinidad or Tobago or Tunisia or Turkey or Turkmenistan or Turkmen or Uganda or Ukraine or Uruguay or USSR or Soviet Union or Union of Soviet Socialist Republics or Uzbekistan or Uzbek or Vanuatu or New Hebrides or Venezuela or Vietnam or Viet Nam or West Bank or Yemen or Yugoslavia or Zambia or Zimbabwe or Rhodesia).hw,kf,ti,ab,cp.319173678((developing or less\* developed or under developed or underdeveloped or middle income or low\* income or underserved or under served or deprived or poor\*) adj (countr\* or nation? or population? or world)).ti,ab.7100179((developing or less\* developed or under developed or underdeveloped or middle income or low\* income) adj (economy or economies)).ti,ab.35880(low\* adj (gdp or gnp or gross domestic or gross national)).ti,ab.18781(low adj3 middle adj3 countr\*).ti,ab.654882(lmic or lmics or third world or lami countr\*).ti,ab.426683transitional countr\*.ti,ab.12784or/75‐83334976685randomized controlled trial.pt.42132586controlled clinical trial.pt.9103587pragmatic clinical trial.pt.34288multicenter study.pt.20484089non‐randomized controlled trials as topic/6690interrupted time series analysis/16391controlled before‐after studies/14692(randomis\* or randomiz\* or randomly or random allocat\*).ti,ab.67646893groups.ab.160197194(trial or multicenter or multi center or multicentre or multi centre).ti.18405195(intervention\* or controlled or control group or compare or compared or (before adj5 after) or (pre adj5 post) or pretest or pre test or posttest or post test or quasiexperiment\* or quasi experiment\* or evaluat\* or effect or impact or time series or time point? or repeated measur\*).ti,ab.785918696or/85‐95859675097Animals/589959498Humans/160880339997 not (97 and 98)4232417100comment.pt.673136101editorial.pt.409272102cochrane database of systematic reviews.jn.12472103comment on.cm.673135104review.pt.2144868105review.ti.325750106or/99‐105725366210796 not 10661929621081 and 84 and 1071161097 and 33 and 84 and 10763551107 and 47 and 84 and 1079321117 and 60 and 84 and 10733761127 and 74 and 84 and 1072768113or/108‐1127596

**Embase, OvidSP**

**\#SearchesResults**1(privat\* adj6 (public\* or stewardship\* or governance or governing or coordinat\* or co ordinat\* or legislat\* or regulat\* or government\* or law or laws or act or acts or policy or policies or politics or reform\* or control\* or supervis\* or monitor\*)).ti,ab.230792(privat\* adj6 (competence or practice pattern\* or malpractice or mal practice or error\*)).ti,ab.1163(privat\* adj6 (educat\* or train or training or trained or colloquium? or conference? or course? or lecture? or meeting? or seminar? or support\* or symposi\* or workshop?)).ti,ab.28174(privat\* adj6 (best practice or quality or standard\* or benchmark\* or adherence or requirement\*)).ti,ab.13295or/1‐4257166Developing Country.sh.786007(Africa or Asia or Caribbean or West Indies or South America or Latin America or Central America).hw,ti,ab,cp.2425198(Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or Argentina or Armenia or Armenian or Aruba or Azerbaijan or Bahrain or Bangladesh or Barbados or Benin or Byelarus or Byelorussian or Belarus or Belorussian or Belorussia or Belize or Bhutan or Bolivia or Bosnia or Herzegovina or Hercegovina or Botswana or Brasil or Brazil or Bulgaria or Burkina Faso or Burkina Fasso or Upper Volta or Burundi or Urundi or Cambodia or Khmer Republic or Kampuchea or Cameroon or Cameroons or Cameron or Camerons or Cape Verde or Central African Republic or Chad or Chile or China or Colombia or Comoros or Comoro Islands or Comores or Mayotte or Congo or Zaire or Costa Rica or Cote d\'Ivoire or Ivory Coast or Croatia or Cuba or Cyprus or Czechoslovakia or Czech Republic or Slovakia or Slovak Republic or Djibouti or French Somaliland or Dominica or Dominican Republic or East Timor or East Timur or Timor Leste or Ecuador or Egypt or United Arab Republic or El Salvador or Eritrea or Estonia or Ethiopia or Fiji or Gabon or Gabonese Republic or Gambia or Gaza or Georgia Republic or Georgian Republic or Ghana or Gold Coast or Greece or Grenada or Guatemala or Guinea or Guam or Guiana or Guyana or Haiti or Honduras or Hungary or India or Maldives or Indonesia or Iran or Iraq or Isle of Man or Jamaica or Jordan or Kazakhstan or Kazakh or Kenya or Kiribati or Korea or Kosovo or Kyrgyzstan or Kirghizia or Kyrgyz Republic or Kirghiz or Kirgizstan or Lao PDR or Laos or Latvia or Lebanon or Lesotho or Basutoland or Liberia or Libya or Lithuania or Macedonia or Madagascar or Malagasy Republic or Malaysia or Malaya or Malay or Sabah or Sarawak or Malawi or Nyasaland or Mali or Malta or Marshall Islands or Mauritania or Mauritius or Agalega Islands or Mexico or Micronesia or Middle East or Moldova or Moldovia or Moldovian or Mongolia or Montenegro or Morocco or Ifni or Mozambique or Myanmar or Myanma or Burma or Namibia or Nepal or Netherlands Antilles or New Caledonia or Nicaragua or Niger or Nigeria or Northern Mariana Islands or Oman or Muscat or Pakistan or Palau or Palestine or Panama or Paraguay or Peru or Philippines or Philipines or Phillipines or Phillippines or Poland or Portugal or Puerto Rico or Romania or Rumania or Roumania or Russia or Russian or Rwanda or Ruanda or Saint Kitts or St Kitts or Nevis or Saint Lucia or St Lucia or Saint Vincent or St Vincent or Grenadines or Samoa or Samoan Islands or Navigator Island or Navigator Islands or Sao Tome or Saudi Arabia or Senegal or Serbia or Montenegro or Seychelles or Sierra Leone or Slovenia or Sri Lanka or Ceylon or Solomon Islands or Somalia or Sudan or Suriname or Surinam or Swaziland or Syria or Tajikistan or Tadzhikistan or Tadjikistan or Tadzhik or Tanzania or Thailand or Togo or Togolese Republic or Tonga or Trinidad or Tobago or Tunisia or Turkey or Turkmenistan or Turkmen or Uganda or Ukraine or Uruguay or USSR or Soviet Union or Union of Soviet Socialist Republics or Uzbekistan or Uzbek or Vanuatu or New Hebrides or Venezuela or Vietnam or Viet Nam or West Bank or Yemen or Yugoslavia or Zambia or Zimbabwe or Rhodesia).hw,ti,ab,cp.29721049((developing or less\* developed or under developed or underdeveloped or middle income or low\* income or underserved or under served or deprived or poor\*) adj (countr\* or nation? or population? or world)).ti,ab.7377410((developing or less\* developed or under developed or underdeveloped or middle income or low\* income) adj (economy or economies)).ti,ab.38211(low\* adj (gdp or gnp or gross domestic or gross national)).ti,ab.20712(low adj3 middle adj3 countr\*).ti,ab.514713(lmic or lmics or third world or lami countr\*).ti,ab.407814transitional countr\*.ti,ab.15715or/6‐14316447316Randomized Controlled Trial/36841617Controlled Clinical Trial/39046718Quasi Experimental Study/234819Pretest Posttest Control Group Design/22620Time Series Analysis/1520821Experimental Design/1099022Multicenter Study/11979023(randomis\* or randomiz\* or randomly or random allocat\*).ti,ab.78449224groups.ab.181865325(trial or multicentre or multicenter or multi centre or multi center).ti.20918226(intervention\* or controlled or control group or compare or compared or (before adj5 after) or (pre adj5 post) or pretest or pre test or posttest or post test or quasiexperiment\* or quasi experiment\* or evaluat\* or effect or impact or time series or time point? or repeated measur\*).ti,ab.856260927or/16‐26933648928review.ti.32085029\"cochrane database of systematic reviews\".jn.377130Nonhuman/449436631or/28‐3047958753227 not 317358995335 and 15 and 32422734limit 33 to embase2929

**Science Citation Index; Social Sciences Citation Index, ISI Web of Knowledge**

TOPIC: (\"public stewardship\" or \"public partnership\") OR TOPIC: ((privat\*) AND (stewardship\* or governance or governing or policy or policies or politics or coordinat\* or legislat\* or regulat\* or supervis\* or monitor\*) AND (health\* or medical\* or pharmac\* or drug or drugs or doctor\* or physician\* or nurse or nurses or hospital\*) AND (((developing or \"less developed\" or \"lesser developed\" or underdeveloped or \"under developed\" or \"middle income\" or \"low income\" or \"lower income\" or transitional) AND (countr\* or nation\* or population\* or world)) or (lmic or lmics)) AND (randomis\* or randomiz\* or impact or effect or evaluat\* or control\* or intervention\* or \"time series\" or \"time point\" or \"time points\" or \"repeated measure\" or \"repeated measures\" or quasiexperiment\* or \"quasi experiment\")) OR TOPIC: ((privat\*) AND (public\*) AND (partnership\* or engagement\* or collaborat\*) AND (health\* or medical\* or pharmac\* or drug or drugs or doctor\* or physician\* or nurse or nurses or hospital\*) AND (((developing or \"less developed\" or \"lesser developed\" or underdeveloped or \"under developed\" or \"middle income\" or \"low income\" or \"lower income\" or transitional) AND (countr\* or nation\* or population\* or world)) or (lmic or lmics)) AND (randomis\* or randomiz\* or impact or effect or evaluat\* or control\* or intervention\* or \"time series\" or \"time point\" or \"time points\" or \"repeated measure\" or \"repeated measures\" or quasiexperiment\* or \"quasi experiment\"))

**Global Health, OvidSP**

**\#SearchesResults**1(public stewardship or public partnership\*).mp.432(private and public and (stewardship or governance or governing or policy or policies or politics or coordinate or coordination or co ordinate or co ordination or legislate or legislation or regulat\* or supervise or supervision or monitor or monitoring or partnership or partnerships or engagement or collaborate or collaboration or collaborating) and (randomised or randomized or random allocation or randomly allocated or impact or impacts or effect or effects or evaluate or control group or control groups or controlled or intervention or time series or time point or time points or repeated measur\* or quasiexperiment\* or quasi experiment\*)).mp.112731 or 21157

**WHOLIS, WHO**

words or phrase: \"public stewardship\$ or public partnership\$\"

**Health Management, ProQuest**

(Two strategies)

1\. ALL(\"public stewardship\" or \"public partnership\")

2\. ALL(privat\*) and ALL(public\* or stewardship\* or (national NEAR/3 program\*) or governance) and ALL(coordinat\* or (co PRE/0 ordinat\*) or educat\* or train or training or regulat\*) and ALL((Africa or Asia or Caribbean or \"West Indies\" or \"South America\" or \"Latin America\" or \"Central America\" or Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or Argentina or Armenia or Armenian or Aruba or Azerbaijan or Bahrain or Bangladesh or Barbados or Benin or Byelarus or Byelorussian or Belarus or Belorussian or Belorussia or Belize or Bhutan or Bolivia or Bosnia or Herzegovina or Hercegovina or Botswana or Brasil or Brazil or Bulgaria or \"Burkina Faso\" or \"Burkina Fasso\" or \"Upper Volta\" or Burundi or Urundi or Cambodia or \"Khmer Republic\" or Kampuchea or Cameroon or Cameroons or Cameron or Camerons or \"Cape Verde\" or \"Central African Republic\" or Chad or Chile or China or Colombia or Comoros or \"Comoro Islands\" or Comores or Mayotte or Congo or Zaire or \"Costa Rica\" or \"Cote d\'Ivoire\" or \"Ivory Coast\" or Croatia or Cuba or Cyprus or Czechoslovakia or \"Czech Republic\" or Slovakia or \"Slovak Republic\" or Djibouti or \"French Somaliland\" or Dominica or \"Dominican Republic\" or \"East Timor\" or \"East Timur\" or \"Timor Leste\" or Ecuador or Egypt or \"United Arab Republic\" or \"El Salvador\" or Eritrea or Estonia or Ethiopia or Fiji or Gabon or \"Gabonese Republic\" or Gambia or Gaza or \"Georgia Republic\" or \"Georgian Republic\" or Ghana or \"Gold Coast\" or Greece or Grenada or Guatemala or Guinea or Guam or Guiana or Guyana or Haiti or Honduras or Hungary or India or Maldives or Indonesia or Iran or Iraq or \"Isle of Man\" or Jamaica or Jordan or Kazakhstan or Kazakh or Kenya or Kiribati or Korea or Kosovo or Kyrgyzstan or Kirghizia or \"Kyrgyz Republic\" or Kirghiz or Kirgizstan or \"Lao PDR\" or Laos or Latvia or Lebanon or Lesotho or Basutoland or Liberia or Libya or Lithuania or Macedonia or Madagascar or \"Malagasy Republic\" or Malaysia or Malaya or Malay or Sabah or Sarawak or Malawi or Nyasaland or Mali or Malta or \"Marshall Islands\" or Mauritania or Mauritius or \"Agalega Islands\" or Mexico or Micronesia or \"Middle East\" or Moldova or Moldovia or Moldovian or Mongolia or Montenegro or Morocco or Ifni or Mozambique or Myanmar or Myanma or Burma or Namibia or Nepal or \"Netherlands Antilles\" or \"New Caledonia\" or Nicaragua or Niger or Nigeria or \"Northern Mariana Islands\" or Oman or Muscat or Pakistan or Palau or Palestine or Panama or Paraguay or Peru or Philippines or Philipines or Phillipines or Phillippines or Poland or Portugal or Puerto Rico or Romania or Rumania or Roumania or Russia or Russian or Rwanda or Ruanda or \"Saint Kitts\" or \"St Kitts\" or Nevis or \"Saint Lucia\" or \"St Lucia\" or \"Saint Vincent\" or \"St Vincent\" or Grenadines or Samoa or \"Samoan Islands\" or \"Navigator Island\" or \"Navigator Islands\" or \"Sao Tome\" or \"Saudi Arabia\" or Senegal or Serbia or Montenegro or Seychelles or \"Sierra Leone\" or Slovenia or \"Sri Lanka\" or Ceylon or \"Solomon Islands\" or Somalia or Sudan or \"South Africa\" or Suriname or Surinam or Swaziland or Syria or Tajikistan or Tadzhikistan or Tadjikistan or Tadzhik or Tanzania or Thailand or Togo or \"Togolese Republic\" or Tonga or Trinidad or Tobago or Tunisia or Turkey or Turkmenistan or Turkmen or Uganda or Ukraine or Uruguay or USSR or \"Soviet Union\" or \"Union of Soviet Socialist Republics\" or Uzbekistan or Uzbek or Vanuatu or \"New Hebrides\" or Venezuela or Vietnam or\" Viet Nam\" or \"West Bank\" or Yemen or Yugoslavia or Zambia or Zimbabwe or Rhodesia or lmic or lmics or \"third world\" or \"lami country\" or \"lami countries\" or \"transitional country\" or \"transitional countries\") or (developing or \"less developed\" or \"lesser developed\" or \"under developed\" or underdeveloped or \"middle income\" or \"low income\" or \"lower income\" or underserved or \"under served\" or deprived or poor\*) PRE/0 (countr\* or nation\* or population\* or world or economy or economies)) and ALL(randomised or randomized or \"randomly allocated\" or \"random allocation\" or trial or intervention or interventions or controlled or \"control group\" or \"before and after\" or \"pre and post\" or pretest or \"pre test\" or posttest or \"post test\" or quasiexperiment or quasiexperimental or evaluate or effect or impact or \"time series\" or \"time point\" or \"time points\" or \"repeated measure\" or \"repeated measures\" or \"repeated measurement\" or \"repeated measurements\")

**OpenGrey**

((stewardship\* OR partnership\*) OR (privat\* AND public\*)) AND (05T Health services, health administration, community care services)

**The Grey Literature Report**

1\. Keywords:**public stewardship** and tick off for **Grey Literature** under: Collection codes

2\. Title:**public stewardship** and tick off for **Grey Literature** under: Collection codes

3\. Keywords:**private stewardship** and tick off for **Grey Literature** under: Collection codes

4\. Title:**private stewardship** and tick off for **Grey Literature** under: Collection codes

5\. Keywords:**public partnership** and tick off for **Grey Literature** under: Collection codes

6\. Title:**public partnership** and tick off for **Grey Literature** under: Collection codes

7\. Keywords:**private partnership** and tick off for **Grey Literature** under: Collection codes

8\. Title:**private partnership** and tick off for **Grey Literature** under: Collection codes

**World Bank e‐Library**

\[Title: stewardship\* OR partnership\* OR (privat\* AND public\*)\] AND \[Keyword: stewardship\* OR partnership\* OR (privat\* AND public\*)\] AND \[Abstract: stewardship\* OR partnership\* OR (privat\* AND public\*)\]

**International Clinical Trials Registry Platform**

1\. private AND public (in title) and set Recruitment status to ALL

2\. private AND public (in intervention) and set Recruitment status to ALL

3\. stewardship OR stewardships OR partnership OR partnerships (in title) and set Recruitment status to ALL

4\. stewardship OR stewardships OR partnership OR partnerships (in intervention) and set Recruitment status to ALL

**ClinicalTrials.gov**

In Search Terms

(private OR public) AND (stewardship OR stewardships OR partnership OR partnerships)

**US National Institutes of Health**

In Search Terms

(private OR public) AND (stewardship OR stewardships OR partnership OR partnerships)

**United Nations Children\'s Fund**

In Search Terms

(private OR public) AND (stewardship OR stewardships OR partnership OR partnerships)

**Alliance for Health Policy and Systems Research**

In Search Terms

(private OR public) AND (stewardship OR stewardships OR partnership OR partnerships)

**United States Agency for International Development**

In Search Terms

(private OR public) AND (stewardship OR stewardships OR partnership OR partnerships)

**Gavi, The Vaccine Alliance**

In Search Terms

(private OR public) AND (stewardship OR stewardships OR partnership OR partnerships)

**Private Healthcare in Developing Countries**

In Search Terms

(private OR public) AND (stewardship OR stewardships OR partnership OR partnerships)

**Population Services International**

In Search Terms

(private OR public) AND (stewardship OR stewardships OR partnership OR partnerships)

**Shops**

In Search Terms

(private OR public) AND (stewardship OR stewardships OR partnership OR partnerships)

**Department for International Development**

In Search Terms

(private OR public) AND (stewardship OR stewardships OR partnership OR partnerships)

**Center For Health Market Innovations**

In Search Terms

(private OR public) AND (stewardship OR stewardships OR partnership OR partnerships)

**World Bank**

In Search Terms

(private OR public) AND (stewardship OR stewardships OR partnership OR partnerships)

Comparison 1TrainingOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Quality of care](#CD009855-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Training, Outcome 1 Quality of care.1Risk Ratio (M‐H, Fixed, 95% CI)Totals not selected[1.1 RCT studies](#CD009855-fig-00101){ref-type="fig"}1Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][1.2 Non RCT studies](#CD009855-fig-00101){ref-type="fig"}1Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][2 Quality of care](#CD009855-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Training, Outcome 2 Quality of care.1Odds Ratio (Fixed, 95% CI)Totals not selected
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Characteristics of included studies \[ordered by study ID\] {#CD009855-sec2-0018}
===========================================================

Abuya 2009MethodsCluster‐randomised trial conducted in 3 districts in Kenya from 2002‐2005ParticipantsNumber enrolled: 10 clusters (sub‐districts) with a total of 140 functional anti‐malarial medicine \'shops\'\
Study population: 10 divisions (clusters) in 3 rural districts in Kenya (i.e. Kwale, Makueni and Busia ) with divisions as unit of randomisation in Kenya\
Inclusion criteria: the main sellers in outlets stocking anti‐malarial medicines. The eligible outlets had to be relatively stable (on the basis of local knowledge)\
Exclusion criteria: non‐functional anti‐malarial medicine outlets\
Withdrawals and exclusions: in Kwale district, 24% of trainees changed business or closed their outlets. In Makueni and Busia districts, 4% and 5% of trainees respectively closed their outlets within 6--8 months after trainingInterventionsIntervention: 5 divisions (clusters) with 60 functional medicine outlets were allocated to the intervention group. In total, 122 private medical retailers were trained in Kwale, 79 in Busia, and 247 in Makueni districts\
Duration: the intervention consisted of 2‐day training workshops at local venues\
Who delivered the intervention: Kenya\'s Ministry of Health\
Description: the training covered signs of simple and severe malaria; malaria treatment and prevention; drug resistance; referral practices; storage and expiry of medicines; and communication skills\
Comparison: no training was conducted in 5 \'control\' divisions (clusters) with 80 outletsOutcomesRetailers' knowledge on the treatment of childhood fevers; recommended amodiaquine adequately\
Surrogate clients were used to pose as patients and retail audits were used to collect information on the outlets and retailersNotesThe study was approved by the Kenya National Scientific Steering and Ethical Research Committees and the WHO Secretariat Committee on Research Involving Human Subjects (SCRIHS).\
A cost‐effectiveness study of the intervention in Kenya suggested that, although the initial cost of setting such programmes is high, the annual running costs could be contained within a typical district budget. In total, USD 5202.00 and USD 5882.00 were released to Kwale and Makueni districts respectively, for the implementation of the programmes in the setup year. The programme in Busia district was implemented with funds from UNICEF, with a total of USD5838 allocated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo descriptionAllocation concealment (selection bias)Unclear riskNo descriptionBlinding of participants and personnel (performance bias) All outcomesLow riskSurrogate clients, fieldworkers posed as clients seeking care from a provider who was unaware of the clients\' identityBlinding of outcome assessment (detection bias) All outcomesLow riskSurrogate clients, fieldworkers posed as clients seeking care from a provider who was unaware of their identityIncomplete outcome data (attrition bias) All outcomesHigh risk4% and 24% of trained outlets closed within 6--8 months of trainingSelective reporting (reporting bias)Unclear riskNo descriptionOther biasLow riskNo evidence of other sources of biasSimilar baseline characteristicsLow riskThe District Health Management Team in each district identified divisions they considered similar in characteristicsSimilar baseline outcome measuresUnclear riskNo descriptionReliable primary outcome measuresUnclear riskNo descriptionAdequate protection against contaminationHigh riskIt is possible that there was some degree of contamination in Busia district, a suggestion supported by the District Health Management Team report that the district had experienced almost complete coverage with PMR programmes at the time of the evaluation, leaving only one division as the controlChalker 2002MethodsCluster‐randomised trial conducted in Hanoi, Vietnam, conducted from May 1998‐September 1999ParticipantsNumber enrolled: 34 paired pharmacies in urban Hanoi\
Study population: private pharmacies registered in the urban area of Hanoi\
Inclusion criteria: private registered pharmacies in urban Hanoi\
Exclusion criteria: pharmacies outside hospitals and not mainly wholesalers\
Withdrawal and exclusions: in the course of the study, 4 pharmacies closed and 1 refused to take part in the third intervention. No post‐intervention interviews were taken from 4 intervention and 4 control pharmacies as they were closed early before the Vietnamese New Year holidays. These gave 22 matched pairsInterventionsIntervention: regulatory enforcement, face‐to‐face education, and peer influence. The three interventions were implemented sequentially in 22 pharmacies\
Duration: each intervention lasted 3 months, with a gap of 4 months before the next intervention\
Who delivered the intervention: the Hanoi Health Bureau and the Hanoi Pharmacy Association\
Description:\
for the regulatory intervention, 4 inspectors of the Hanoi Health Bureau were trained to undertake the inspection. In pairs the inspectors visited the intervention pharmacies twice, a month apartfor the face‐to‐face education intervention, each intervention pharmacy was visited twice by 2 people who conducted face to‐ face education sessions with all staff present. Each session lasted about 45 minutes and included both written and verbal informationFor the peer influence intervention, a 1‐day seminar was held with the 5 group leaders and representatives of the Hanoi Pharmacy Association\
Comparison: 22 pharmacies with no interventionOutcomesKnowledge and reported change in practice for correct management of tracer conditionsNotesThe cost for the 3 interventions was approximately USD 5700.00 for 30 pharmacies***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo descriptionAllocation concealment (selection bias)Unclear riskNo descriptionBlinding of participants and personnel (performance bias) All outcomesUnclear riskNo descriptionBlinding of outcome assessment (detection bias) All outcomesUnclear riskNo descriptionIncomplete outcome data (attrition bias) All outcomesUnclear riskNo descriptionSelective reporting (reporting bias)Unclear riskNo descriptionOther biasLow riskFailure to interview people from 4 intervention and 4 control pharmacies after the interventions may have caused a bias in results, but this is unlikely because of the equivalent numbers between intervention and controlSimilar baseline characteristicsLow riskThere was matching of pharmacies to ensure similar baseline characteristicsSimilar baseline outcome measuresLow riskThere was a slight difference in the outcome measures at baseline level which was not statistically significantReliable primary outcome measuresUnclear riskNo descriptionAdequate protection against contaminationUnclear riskNo descriptionChalker 2005MethodsRandomised trial conducted in Hanoi (Vietnam) and Bangkok (Thailand) from June 1998‐September 1999ParticipantsNumber enrolled: 68 pharmacies in Hanoi and 78 pharmacies in Bangkok\
Study population: private registered pharmacies in Hanoi and Bangkok\
Inclusion criteria: private pharmacies in Hanoi and Bangkok\
Withdrawals and exclusions: in Bangkok 1 intervention pharmacy and 2 control pharmacies closed down and 3 of each were missed in at least one of the simulated clients\' round of visits. In Hanoi 1 intervention and 3 control pharmacies closed, 1 intervention pharmacy refused to continue, and 4 intervention and 4 control pharmacies had incomplete data for different rounds of client visitsInterventionsIntervention: enforcement of regulations, education, and peer review in 34 pharmacies in Hanoi and 39 pharmacies in Bangkok\
Duration: each intervention lasted 3 months, with a gap of 4 months before the next intervention\
Who delivered the intervention: the Hanoi Provincial Health Bureau, Hanoi Pharmacy Association, Hanoi Medical University, and the Hanoi College of Pharmacy. In Bangkok, the interventions were delivered by the Health System Research Institute, Chulalongkorn University, and the Community Pharmacy Association\
Description\
Regulation: in Hanoi, the intervention pharmacies were visited twice by 2 inspectors. A summary of the regulations on prescription‐only medicine, a letter from the provincial health bureau, and an example of good labelling were handed out to each pharmacy. In Bangkok, the enforcement of regulation was performed by 6 inspectors. The inspectors checked the availability of steroids and steroid prescriptions (if the drug was found) and gave instructions to the seller on the respective regulations. A warning was given about the consequences of violation of the regulationsEducation: in Hanoi, each pharmacy received two 45‐minute educational visits by a pair of senior researchers using both written and verbal information. In Bangkok, the educational intervention was performed in 3 groups. The pharmacy owners and the pharmacy assistants were invited to a 2‐day seminarPeer review: the intervention pharmacies in Hanoi were divided into 5 area groups with 5‐6 pharmacies in each. Each of the 5 area groups held 5 meetings averaging 1 every second week. In Bangkok, prospective peer facilitators were identified among the participants. The researchers initiated a group by visiting these 4‐5 active drugstores in each district and introducing the concept of peer groups for drugstore staff\
Comparison: no intervention on 34 control pharmacies in Hanoi and 39 control pharmacies in BangkokOutcomesChange in the dispensing practices of antibiotics in Hanoi and BangkokNotesThe study had ethical approval from the Karolinska Institute as well as the Ministries of Health in Vietnam and Thailand***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo descriptionAllocation concealment (selection bias)Unclear riskNo descriptionBlinding of participants and personnel (performance bias) All outcomesUnclear riskNo descriptionBlinding of outcome assessment (detection bias) All outcomesUnclear riskNo descriptionIncomplete outcome data (attrition bias) All outcomesHigh riskIn Bangkok 1 intervention pharmacy and 2 control pharmacies closed down, and 3 of each were missed in at least one of the simulated clients\' visits. In Hanoi 1 intervention and 3 control pharmacies closed, 1 intervention pharmacy refused to continue and 4 intervention and 4 control pharmacies had incomplete data for different rounds of client visitsSelective reporting (reporting bias)Unclear riskNo descriptionOther biasLow riskThe study appears to be free of other biasesSimilar baseline characteristicsLow riskSome basic characteristics (i.e. turnover, staff numbers and qualifications) were not possible to judge from the simulated clients\' visit. However, the random selection ensured comparability between intervention and control pharmaciesSimilar baseline outcome measuresLow riskThere were no significant differences in the outcome measures at baseline at intra‐city level but there was a difference in the baseline knowledge at inter‐city levelsReliable primary outcome measuresUnclear riskNo descriptionAdequate protection against contaminationUnclear riskNo descriptionChuc 2002MethodsCluster‐randomised controlled trial conducted from October 1997‐January 2000 in Hanoi, VietnamParticipantsNumber enrolled: 34 pairs of private pharmacies\
Study population: 34 pairs of private pharmacies in Hanoi randomly selected according to the following matching criteria:\
turnover: high, medium, or low according to district inspectors;whether or not the pharmacist was the licence holder;whether or not the pharmacy was close to a hospital; andlocated in a different ward or more than 150 meters from all other pharmacies selected\
Inclusion criteria: private pharmacies in the study area\
Exclusion criteria: pharmacies  located inside a hospital or that were mainly wholesalers were excluded\
Withdrawals and exclusions: 4 pharmacies were excluded because of irregular opening hours. As a consequence, the other pharmacy in each pair was also excluded as the results were analysed in pairsInterventionsIntervention: regulatory enforcement, educational intervention, and peer review\
Duration: each intervention lasted 3 months, with a gap of 4 months before the next intervention\
Who delivered the intervention: Hanoi Bureau Health and Hanoi Pharmacy Association\
Description\
For regulation: 4 inspectors from the Hanoi Health Bureau were trained to cover these areas of inspection. In pairs they visited the intervention pharmacies twice with an interval of 1 monthFor education: 2 senior research team members and 2 clinicians conducted the intervention. Each intervention pharmacy received two 45‐min face‐to‐face educational sessionsPeer review: 5 group leaders conducted a 1‐day seminar where the research group informed about the peer influence strategy and reviewed case management of the 4 tracer conditions. 3 meetings were held during 3 months where the participants presented and discussed their records\
Comparison: no interventionOutcomesEffect of multi‐component intervention using tracer conditions i.e. correct  symptomatic treatment of  sexually transmitted diseaseNotesThe estimated total cost of the interventions was approximately USD 5700.00***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo descriptionAllocation concealment (selection bias)Unclear riskNo descriptionBlinding of participants and personnel (performance bias) All outcomesUnclear riskNo descriptionBlinding of outcome assessment (detection bias) All outcomesUnclear riskNo descriptionIncomplete outcome data (attrition bias) All outcomesHigh risk4 pharmacies were excluded because of irregular opening hours. As a consequence, the other pharmacy in each pair was also excluded as the results were analysed in pairsSelective reporting (reporting bias)Unclear riskNo descriptionOther biasLow riskThe study appears to be free of other sources of biasSimilar baseline characteristicsLow riskThe pharmacies paired to ensure a similar composition for intervention and control groupsSimilar baseline outcome measuresUnclear riskNo descriptionReliable primary outcome measuresUnclear riskNo descriptionAdequate protection against contaminationLow riskTo prevent the client's individual behaviour from affecting the pharmacy staff, all clients were trained to act in a reproducible way, and they were not informed about which pharmacies belonged to the intervention or control groupsRoss‐Degnan 1996MethodsNon‐randomised controlled trial conducted in Kenya\
Randomised controlled trial conducted in IndonesiaDate not statedParticipantsNumber enrolled: 112 pharmacies in Kenya and 87 pharmacies in Indonesia\
Study population\
In Kenya, the study was done in Nairobi, Nakuru and MombasaIn Indonesia the pharmacies were selected from Jakarta and the neighbouring communities of Bogor, Tangerang, and Bekasi\
Inclusion criteria: private pharmacy in the study area\
Withdrawals and exclusions: Four pharmacies in Kenya and five pharmacies in Indonesia were excluded because the analyses were limited to the outcomes that were measured both before and after the interventionInterventionsIntervention: training in 82 pharmacies in Kenya and 43 pharmacies in Indonesia\
Duration: 1 day in Kenya and 2 days in Indonesia\
Who delivered the intervention: Control of Diarrhoea Diseases (CDD) programmes in the Ministry of Health\
Description: in both countries, the intervention began with brief one‐on‐one meetings with pharmacists/pharmacy owners discussing key training messages and ways to deal with perceived barriers to practice recommendations, followed by training of all counter attendants in group sessions of 5‐10 attendees organised close to their pharmacies. To measure changes in treatment practice, all pharmacies included in the study in both countries were visited by surrogate patients.\
Comparison: the no‐training control group consisted of 25 pharmacies in Kenya and 44 pharmacies in IndonesiaOutcomesProportion of cases who received oral rehydration salts (ORS)Notes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo descriptionAllocation concealment (selection bias)Unclear riskNo descriptionBlinding of participants and personnel (performance bias) All outcomesLow riskTrainees and pharmacy owners were not informed that the sales practices in their pharmacies would be evaluatedBlinding of outcome assessment (detection bias) All outcomesLow riskOutcomes were assessed by surrogate patients who were blind to the purpose of the study, and to the study or control status of the pharmaciesIncomplete outcome data (attrition bias) All outcomesUnclear riskNo descriptionSelective reporting (reporting bias)Unclear riskNo descriptionOther biasLow riskThe study appears to be free of other sources of biasSimilar baseline characteristicsLow riskThere were similar baseline characteristicsSimilar baseline outcome measuresUnclear riskNo descriptionReliable primary outcome measuresUnclear riskNo descriptionAdequate protection against contaminationUnclear riskNo descriptionStenson 2001MethodsRandomised controlled trial conducted from June 1997 to March 1999 in the Lao People\'s Democratic Republic (Lao P.D.R.)ParticipantsNumber enrolled: 115 pharmacies\
Study population: the study was based on licensed private pharmacies in Savannakhet province, Lao P.D.R. All pharmacies except 2 belonged to class 3, the lowest class of licensed pharmacies, where the licensee does not have to be a pharmacist or an assistant pharmacist. Most of them had a nursing background\
Inclusion criteria: operating pharmacy within the province\
Exclusion criteria: the pharmacies that were missed in the (post‐intervention analysis) were excluded from the analysis\
Withdrawals and exclusions: 14 pharmacies were missed during study and the reasons for missing pharmacies were mortality among drug sellers or that the pharmacy had moved or was closed for family reasonsInterventionsIntervention: active regulation in 46 pharmacies\
Duration: One and half years\
Who delivered the intervention: Ministry of Health with assistance from UNICEF\
Description: the regulatory intervention involved three month\'s intensive supervision of the quality of pharmacy services, applying sanctions when rules were violated, and providing up‐to‐date regulatory documents and information about particular areas needing improvements. The study compared districts with active regulation to districts with regular care\
Comparison: 92 control pharmacies received regular careOutcomesChange of the quality of private pharmacy practice (pharmacy indicators)Notes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo descriptionAllocation concealment (selection bias)Unclear riskNo descriptionBlinding of participants and personnel (performance bias) All outcomesUnclear riskIt was not possible to make the study blinded with regard to the main intervention vehicle, the research assistant. It could not be established to what extent the drug sellers had any active knowledge of the study objectivesBlinding of outcome assessment (detection bias) All outcomesUnclear riskThe district pharmacists who were active partners in the research team and participated in the sampling procedures and assessing the outcome were also aware of the scope of the interventionIncomplete outcome data (attrition bias) All outcomesHigh risk14 pharmacies were missed during the study and the reasons for missing pharmacies were mortality among drug sellers or that the pharmacy had moved or was closed for family reasonsSelective reporting (reporting bias)Unclear riskNo descriptionOther biasLow riskThe study appears to be free of other sources of biasSimilar baseline characteristicsLow riskThere were similar baseline characteristics i.e. income levels and literacySimilar baseline outcome measuresUnclear riskNo descriptionReliable primary outcome measuresUnclear riskNo descriptionAdequate protection against contaminationUnclear riskNo description[^2]

Characteristics of excluded studies \[ordered by study ID\] {#CD009855-sec2-0019}
===========================================================

StudyReason for exclusionAkol 2014This was a cross‐sectional studyAkoria 2008This was a controlled before‐after study but the participants were not private‐for‐profit providersAli 2011This was a cross‐sectional studyAli 2012This was a cross‐sectional surveyAndrianasolo 2012This was a prospective descriptive studyBhat 1996This was a cross‐sectional studyBin 2013A controlled before‐after study with single unit for intervention and control armsBojalil 1999This was a controlled before‐after study and the participants were described as private providers, but it is not clear if these were for‐profit or not‐for‐profit healthcare providersChakraborty 2000This was an uncontrolled before‐after study designContiades 2007This was a descriptive studyDholakia 2013This was a descriptive study of an intervention administered through a non‐governmental organisationFarsi 1999This was a randomised trial but its not clear who delivered the interventionFernandes 2009This was a before‐after study and the intervention was undertaken among school children and not healthcare providersGoodman 2007This was a cross‐sectional studyGrundy 2010This was a cross‐sectional studyGuiscafre 2001This was a cross‐sectional studyHarrison 2000This was a randomised trial; but the intervention was not implemented by the public sector, and participants were not private‐for‐profit providersHongoro 2000This was a cross‐sectional studyHulda 2015A controlled before‐after study with single unit for intervention and control armsKangwana 2011This was a randomised trial; but the intervention was not implemented by the public sector, and participants were not private‐for‐profit providersKhan 2006This was a cross‐sectional studyKumaranayake 2000This was a cross‐sectional studyMaiga 2010This was a cross‐sectional studyMarsh 2004This was a cross‐sectional studyMinh 2013This was a cross‐sectional studyMorris 2013This was an uncontrolled before‐after studyMurugesan 2009This was a cross‐sectional studyNsimba 2007This was a cross‐sectional studyObua 2004This was a controlled before‐after study, but it is not clear whether the participants were private not‐for‐profit or private for‐profit providersOkonofua 2003This was a randomised trial, but the intervention was offered by the private sector rather than the public sectorOsterholt 2009This was a time series study, with one measure before and two measures after introduction of the intervention. This does not meet our criteria for eligible interrupted time series studies i.e. at least three measurements before and after introducing the interventionRutta 2011This was a descriptive pilot studyRutta 2015This was a prospective descriptive studyStenson 2001bThis was a cross‐sectional studySyhakhang 2001This was a cross‐sectional studyTavrow 2003This was a cross‐sectional studyTumwikirize 2004This was a non‐randomised trial but it is not clear who offered the interventionWard 2013This was an uncontrolled before‐after studyWilley 2014The intervention was not administered on participants

Characteristics of studies awaiting assessment \[ordered by study ID\] {#CD009855-sec2-0020}
======================================================================

Ansah 2015MethodsCluster‐randomised trial in Dangme West, a poor rural district of Ghana, from August 2011‐January 2013ParticipantsDrug sellers in registered chemical shops within 24 community clustersInterventionsIntervention: training on malaria rapid diagnostic tests and appropriate malaria case management\
Comparison: standard careOutcomesChange of practice in malaria diagnosis and antimalarial prescriptionNotesEl‐Khoury 2015MethodsRandomised trial in two regions in Jordan, between January 2012 and January 2013Participants267 private doctors who provide family planning services in Amman and Zarqa regions in JordanInterventionsIntervention: evidence‐based medicine seminar on depot medroxy progesterone acetate and two educational visits to reinforce the messages from the seminar\
Comparison: invited to the seminar, but were not offered the educational visitsOutcomesProviders' knowledge, attitudes, practices regarding depot medroxy progesterone acetateNotesKafle 2013MethodsRandomised trial in three geographical regions of NepalParticipants342 drug sellers in private pharmacies in 12 districts in NepalInterventionsIntervention 1: mailed printed educational materials followed by mailed feedback\
Intervention 2: small group training followed by feedback\
Intervention 3: small group training only\
Comparison group: no interventionOutcomesQuality of management of acute respiratory infections and diarrhoea in children, and anaemia in pregnancyNotesMbonye 2015MethodsCluster‐randomised trial in Mukono district, central Uganda, from October 2010‐July 2012ParticipantsDrug sellers in 20 geographical clusters of registered drug shopsInterventionsIntervention: training to perform malaria rapid diagnostic tests to inform malaria case management\
Comparison: current practice of presumptive clinical diagnosis and treatment of feverOutcomesProportion of patients receiving appropriate treatment with artemisinin‐based combination therapyNotesSanta‐Ana‐Tellez 2016MethodsInterrupted time series among private sectors in Mexico and Brazil from the first quarter of 2007 to the first quarter of 2013ParticipantsDescribed as private providersInterventionsOver‐the‐counter antibiotic sales restrictionsOutcomesChanges in the use of non‐steroidal anti‐inflammatory drugs, non‐opioid analgesics, and cough and cold medicines and their relation with the use of antibioticsNotes

Charles Wiysonge and Leila Abdullahi conceived the review, were involved in all stages of the study, and share joint first authorship. All authors participated in the preparation and final approval of the review for publication.
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[^1]: Editorial Group: Cochrane Effective Practice and Organisation of Care Group.

[^2]: UNICEF: The United Nations Children\'s Fund WHO: World Health Organization
